AU2017219204A1

AU2017219204A1 - Sulfonylureas and related compounds and use of same

Info

Publication number: AU2017219204A1
Application number: AU2017219204A
Authority: AU
Inventors: Rebecca Coll; Matthew Cooper; Angus Murray Macleod; David John Miller; Luke O'neill; Avril Robertson; Kate SCHRODER
Original assignee: University of Queensland UQ; College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Current assignee: University of Queensland UQ; College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date: 2016-02-16
Filing date: 2017-02-16
Publication date: 2018-08-23
Also published as: JP2019512009A; CN109071454A; AR109348A1; MX2018009840A; EP3416948C0; BR112018016671A2; HK1257569A1; EP3416948B1; US11858922B2; MA44225A; CA3014487A1; IL261035A; US20200299284A1; EP3416948A1; UY37362A; CN109071454B; KR20180133244A; SG11201806745RA; WO2017140778A1

Abstract

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W

Description

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prod rugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W¹ and W², when present, are independently selected from N and C; R¹ and R² are independently selected from the group consisting of hydrogen, Ci-Ci2alkyl, C2-Ci2alkenyl, C2Ci2alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W¹ and W² is present and is a nitrogen atom and when R¹ and R²are cyclic then the respective W¹ or W² may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflam masome mediated disorders, and to associated diagnostic uses.

WO 2017/140778

PCT/EP2017/053498

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

FIELD OF THE INVENTION [0001 ] The invention relates to the field of medical treatment and diagnosis of disease. More particularly, this invention relates to novel sulfonylurea and related compounds and their use in treating, or identifying a disease or condition responsive to inhibition of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

BACKGROUND TO THE INVENTION [0002] Any reference to background art herein is not to be construed as an admission that such art constitutes common general knowledge in Australia or elsewhere.

[0003] The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrinassociated periodic syndromes (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer’s disease and atherosclerosis.

[0004] NLRP3 is an intracellular signalling molecule that senses many pathogen-derived, environmental and host-derived factors. Upon activation, NLRP3 binds to apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). ASC then polymerises to form a large aggregate known as an ASC speck. Polymerised ASC in turn interacts with the cysteine protease caspase-1 to form a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the proinflammatory cytokines IL-1 β and IL-18 to their active forms and mediates a type of inflammatory cell death known as pyroptosis. The ASC speck can also recruit and activate caspase-8, which can process pro-1L-1 β and pro-1L-18 and trigger apoptotic cell death.

WO 2017/140778

PCT/EP2017/053498 [0005] Caspase-1 cleaves pro-IL-1 β and pro-IL-18 to their active forms, which are secreted from the cell. Active caspase-1 also cleaves gasdermin-D to trigger pyroptosis. Through its control of the pyroptotic cell death pathway, caspase-1 also mediates the release of alarmin molecules such as IL-33 and high mobility group box 1 protein (HMGB1). Caspase-1 also cleaves intracellular IL-1R2 resulting in its degradation and allowing the release of IL1 oc. In human cells caspase-1 may also control the processing and secretion of IL-37. A number of other caspase-1 substrates such as components of the cytoskeleton and glycolysis pathway may contribute to caspase-1-dependent inflammation.

[0006] NLRP3-dependent ASC specks are released into the extracellular environment where they can activate caspase-1, induce processing of caspase1 substrates and propagate inflammation.

[0007] Active cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape the immune response to infection and injury. For example, ΙΙ_-1β signalling induces the secretion of the pro-inflammatory cytokines IL-6 and TNF. IL-1 β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by γδ T cells in the absence of T cell receptor engagement. IL18 and IL-12 also synergise to induce IFN-γ production from memory T cells and NK cells driving a Th1 response.

[0008] Other intracellular pattern recognition receptors (PRRs) are also capable of forming inflammasomes. These include other NLR family members such as NLRP1 and NLRC4, as well as non-NLR PRRs such as the doublestranded DNA (dsDNA) sensors absent in melanoma 2 (AIM2) and interferon, gamma inducible protein 16 (IFI16). NLRP3-dependent IL-1 β processing can also be activated by an indirect, non-canonical pathway downstream of caspase-11.

WO 2017/140778

PCT/EP2017/053498 [0009] The inherited CAPS diseases Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome and neonatal-onset multisystem inflammatory disease are caused by gain-of-function mutations in NLRP3, thus defining NLRP3 as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of a number of complex diseases, notably including metabolic disorders such as type 2 diabetes, atherosclerosis, obesity and gout.

[0010] A role for NLRP3 in diseases of the central nervous system is emerging, and lung diseases have also been shown to be influenced by NLRP3. Furthermore, NLRP3 has a role in the development of liver disease, kidney disease and aging. Many of these associations were defined using Nlrp3~~ mice, but there have also been insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes, the deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1 β signaling, resulting in cell death and inflammation.

[0011] Several small molecules have been shown to inhibit the NLRP3 inflammasome. Glyburide inhibits IL-Ιβ production at micromolar concentrations in response to the activation of NLRP3 but not NLRC4 or NLRP1. Other previously characterised NLRP3 inhibitors include parthenolide,

3,4-methylenedioxy-3-nitrostyrene and dimethyl sulfoxide (DMSO), although these agents have limited potency and are nonspecific.

[0012] Current treatments for NLRP3-related diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist anakinra, the neutralizing IL-1 β antibody canakinumab and the soluble decoy IL-1 receptor rilonacept. These approaches have proven successful in the treatment of CAPS, and these biologic agents have been used in clinical trials for other IL-1 β-associated diseases.

[0013] Certain diarylsulfonylurea-containing compounds have been identified as cytokine release inhibitory drugs (CRIDs) (Perregaux et al.; J.

WO 2017/140778

PCT/EP2017/053498

Pharmacol. Exp. Ther. 299, 187-197, 2001). CRIDs are a class of diarylsulfonylurea containing compounds that inhibit the post-translational processing of IL-1 β. Post-translational processing of IL-1 β is accompanied by activation of caspase-1 and cell death. CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.

[0014] Certain sulfonylurea-containing compounds are also disclosed as inhibitors of NLRP3 (Baldwin et al., J. Med. Chem., 59(5), 1691 -1710, 2016).

[0015] There is a need to provide compounds with improved pharmacological and/or physiological and/or physicochemical properties and/or those that provide a useful alternative to known compounds.

SUMMARY OF INVENTION [0016] According to a first aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

Formula (I) wherein, Q is selected from O, S and Se;

J is S or Se;

W¹ and W², when present, are independently selected from N and C;

R¹ and R² are independently selected from the group consisting of hydrogen, Ci-Ci₂ alkyl, C2-C12 alkenyl, C₂-Ci₂ alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and

WO 2017/140778

PCT/EP2017/053498 wherein at least one of W¹ and W² is present and is a nitrogen atom and when R¹ or R² are cyclic then the respective W¹ or W² may form part of the ring structure.

[0017] According to a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

[0018] A third aspect of the invention resides in a method of treatment or prevention of a disease, disorder or condition including the step of administering an effective amount of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect to thereby treat or prevent the disease, disorder or condition.

[0019] A fourth aspect of the invention provides for a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect for use in the treatment or prevention of a disease, disorder or condition.

[0020] A fifth aspect of the invention provides for use of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition.

[0021 ] In one embodiment, the disease, disorder or condition is responsive to inhibition of activation of the NLRP3 inflammasome.

[0022] In particular non-limiting embodiments of the above aspects, the disease, disorder or condition is a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the respiratory system, the central nervous system, is a cancer or other malignancy and/or is caused by or associated with a pathogen.

WO 2017/140778

PCT/EP2017/053498 [0023] In a sixth aspect of the invention there is provided a method of diagnosing a disease, disorder or condition in a mammal including the step of administering a labelled compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, to the mammal or to a biological sample obtained from the mammal to facilitate diagnosis of the disease, disorder or condition in the mammal.

[0024] A seventh aspect of the invention resides in a method of modulating the activity of a biological target comprising the step of exposing the biological target to a compound of the first aspect, or a pharmaceutically acceptable salt thereof.

[0025] The biological target may be selected from the group consisting of the NLRP3 inflammasome, IL-1 β, IL-17, IL-18, IL-1 oc, IL-37, IL-33 and Th17 cells.

[0026] The various features and embodiments of the present invention, referred to in individual sections above apply, as appropriate, to other sections, mutatis mutandis. Consequently features specified in one section may be combined with features specified in other sections as appropriate.

[0027] Further features and advantages of the present invention will become apparent from the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS [0028] In order that the invention may be readily understood and put into practical effect, preferred embodiments will now be described by way of example with reference to the accompanying figures wherein:

[0029] FIG 1 is a series of isothermal titration calorimetry (ITC) showing a) control experiments: Ca²⁺ binding to EDTA (top left) and Cu²⁺ binding to EDTA (bottom left), together with b) data showing no binding of MCC950 (sodium salt) to Ca²⁺ (top right), but significant binding to Cu²⁺ (bottom right).

WO 2017/140778

PCT/EP2017/053498

DETAILED DESCRIPTION [0030] The present invention is predicated, at least in part, on the finding that certain sulfonyl ureas and related compounds have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome and/or inhibition of IL-1 β and/or IL-17 and/or IL-18, and/or IL-1 oc, and/or IL-37, and/or IL-33 as well as interfere with or modulate the activity of T helper cells such as Th17. Particularly, the compounds of the invention are useful in the treatment of a wide range of disorders in which the inflammation process, or the NLRP3 inflammasome and/or IL-1 β and/or IL-17 and/or IL-18, and/or IL-1 oc, and/or IL-37, and/or IL-33 and/or Th17 cells play a part.

[0031] Evidence from human CAPS patients and mouse models of CAPS has lead the present inventors to believe that NLRP3 inhibition will be a superior treatment over IL-1 biologies, as inhibition of all NLRP3-dependent processes will be more effective than inhibition of a single NLRP3-dependent process, such as IL-1 signalling.

[0032] Individuals with CAPS display dysregulated secretion of both IL-1 β and IL-18, and CAPS patients treated with anti-IL-1 biologies have residual disease. Symptoms such as bony overgrowth and joint deformity are not prevented by IL-1 biologies. In addition, symptoms involving the central nervous system such as hearing loss are difficult to control using IL-1 biologies, which appear to poorly penetrate the central nervous system. Studies in mouse models of CAPS indicate that deficiency in either IL-1 signalling or IL-18 alone is insufficient to block systemic inflammation, particularly in older animals. In a severe model of CAPS, only a complete loss of caspase-1 signalling fully rescued the disease.

[0033] Specific inhibition of NLRP3 by sulfonyurea-containing compounds, such as those of the first aspect, may block all processes downstream of

NLRP3, including ASC speck formation and caspase-8 and caspase-1 activation. Consequently, NLRP3 inhibition will block all caspase-1 dependent

WO 2017/140778

PCT/EP2017/053498 processes such as IL-1 β, IL-18 and IL-37 processing and secretion, gasdermin D cleavage, pyroptosis, and release of IL-1 oc, IL-33 and HMGB. Furthermore, NLRP3-dependent extracellular release of the ASC speck will be blocked, and caspase-8-dependent pro-IL-1 β and pro-IL-18 cleavage and apoptotic cell death will be prevented. Thus, specific inhibition of NLRP3 by compounds of the first aspect will prevent multiple downstream inflammatory signals and should therefore prove more effective as an anti-inflammatory therapy than IL-1 blockade alone.

[0034] Anti-IL-1 biologies block IL-1 derived from NLRP3-independent sources, such as IL-1 produced by other inflammasomes (e.g. NLRC4, NLRP1, NLRP6, AIM2), and IL-1 generated by the latter pathways may be important for host defence against pathogens. For example, patients receiving IL-1/IL-1R antagonists exhibit increased incidence of upper airway infections. Specific inhibition of NLRP3 by the present compounds may thus exert less generalised immunosuppression compared to anti-IL-1 biologies.

[0035] IL-1 β and IL-18, generated by the NLRP3/caspase-1 axis, play critical roles in driving IL-17 production by CD4 Th17 cells and γδ T cells. IL-1 β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by γδ T cells in the absence of TCR engagement. IL-1-driven IL-17 has also been implicated in psoriasis, type I diabetes, rheumatoid arthritis, type 2 diabetes mellitus, atherosclerosis, obesity, gout, and recently, asthma.

[0036] In essence, each of these diseases has been shown to involve the activation of tissue macrophages, dendritic cells, or brain microglia, driven by the frustrated phagocytosis of metabolites that accumulate extracellularly. NLRP3 senses this phagocytic event, leading to IL-1 release, triggering inflammation to clear the offensive material. Disease will result if this process becomes chronic or over-activated, which explains why so many diseases have been shown to involve NLRP3. Inhibitors that act to prevent NLRP3 activation hence can have utility in IL-17 driven, as well as IL-1 driven diseases.

WO 2017/140778

PCT/EP2017/053498 [0037] In this patent specification, the terms ‘comprises’, ‘comprising’, ‘includes’, ‘including’, or similar terms are intended to mean a non-exclusive inclusion, such that a method or composition that comprises a list of elements does not include those elements solely, but may well include other elements not listed.

[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as would be commonly understood by those of ordinary skill in the art to which this invention belongs.

[0039] The term pharmaceutically acceptable salt, as used herein, refers to salts which are toxicologically safe for systemic or localised administration such as salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. The pharmaceutically acceptable salts may be selected from the group including alkali and alkali earth, ammonium, aluminium, iron, glucosamine, chloride, sulphate, sulphonate, bisulphate, nitrate, citrate, tartrate, bitartrate, phosphate, carbonate, bicarbonate, malate, maleate, napsylate, fumarate, succinate, acetate, benzoate, terephthalate, palmoate, piperazine, pectinate and S-methyl methionine salts and the like.

[0040] The term alkyl' refers to a straight-chain or branched alkyl substituent containing from, for example, 1 to about 12 carbon atoms, preferably 1 to about 9 carbon atoms, more preferably 1 to about 6 carbon atoms, even more preferably from 1 to about 4 carbon atoms, still yet more preferably from 1 to 2 carbon atoms. Examples of alkyl groups may be selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isoamyl, 2-methylbutyl, 3-methylbutyl, hexyl, heptyl,

2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-ethylbutyl, 3-ethylbutyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The number of carbons referred to relates to the carbon backbone and carbon branching, but does not include carbon atoms belonging to any substituents, for example the carbon atoms of

WO 2017/140778

PCT/EP2017/053498 an alkoxy substituent branching off the main carbon chain. Substituted alkyl includes alkyl substituted with one or more moieties selected from the group consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl (e.g., CF₃,2-Br-ethyl, CH₂F, CH₂CI, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of “optionally substituted”. An “alkylene” group is similarly defined as a divalent alkyl group.

[0041] The term alkenyl' refers to unsaturated linear or branched hydrocarbon groups, having 2 to 12 carbon atoms, preferably 2 to 9 carbon atoms, more preferably 2 to 6 carbon atoms, and having at least one carboncarbon double bond. Where appropriate, the alkenyl group may have a specified number of carbon atoms, for example, C₂-C₆ alkenyl which includes alkenyl groups having 2, 3, 4, 5 or 6 carbon atoms in linear or branched arrangements. The number of carbons referred to relates to the carbon backbone and carbon branching, but does not include carbon atoms belonging to any substituents. Examples of alkenyl groups may be selected from the group consisting of ethenyl, propenyl, isopropenyl, butenyl, s- and t-butenyl, pentenyl, hexenyl, hepta-1,3-dienyl, hexa-1,3-dienyl, nona-1,3,5-trienyl and the like. Substituted alkenyl includes alkenyl substituted with one or more moieties selected from the group consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl (e.g., CF₃,2-Br-ethyl, CH₂F, CH₂CI, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of “optionally substituted”. An “alkenylene” group is similarly defined as a divalent alkenyl group.

[0042] The term alkynyl refers to unsaturated linear or branched hydrocarbon groups, having 2 to 12 carbon atoms, preferably 2 to 9 carbon

WO 2017/140778

PCT/EP2017/053498 atoms, more preferably 2 to 6 carbon atoms, and having at least one carboncarbon triple bond. Where appropriate, the alkynyl group may have a specified number of carbon atoms, for example, C₂-C₆ alkynyl which includes alkynyl groups having 2, 3,4, 5 or 6 carbon atoms in linear or branched arrangements. The number of carbons referred to relates to the carbon backbone and carbon branching, but does not include carbon atoms belonging to any substituents. Examples of alkynyl groups may be selected from the group consisting of ethynyl, propargyl, but-1-ynyl, but-2-ynyl and the like. Substituted alkynyl includes alkynyl substituted with one or more moieties selected from the group consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl (e.g., CF₃,2-Br-ethyl, CH₂F, CH₂CI, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of “optionally substituted”. An “alkynylene” group is similarly defined as a divalent alkynyl group.

[0043] The term “alkoxy” as used herein means straight or branched chain alkyl groups linked by an oxygen atom (i.e., -O-alkyl), wherein alkyl is as described above. In particular embodiments, alkoxy refers to oxygen-linked groups comprising 1 to 10 carbon atoms (“Cmo alkoxy”). In further embodiments, alkoxy refers to oxygen-linked groups comprising 1 to 8 carbon atoms (“Ci-₈ alkoxy”), 1 to 6 carbon atoms (“Ci-₆ alkoxy”), 1 to 4 carbon atoms (“C1-4 alkoxy”) or 1 to 3 carbon atoms (“Ci-₃ alkoxy”).

[0044] The terms cycloalkyl and “cycloalkenyl” refer to saturated and unsaturated mono-cyclic, bicyclic or tricyclic carbon groups. Where appropriate, the cycloalkyl or cycloalkenyl group may have a specified number of carbon atoms, for example, C₃-C₆ cycloalkyl or cycloalkenyl includes within its scope a carbocyclic group having 3,4, 5 or 6 carbon atoms. Examples of cycloalkyl and cycloalkenyl groups may be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like. Substituted cycloalkyl or cycloalkenyl includes

WO 2017/140778

PCT/EP2017/053498 substitutions with one or more moieties selected from the group consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl (e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂CI, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of “optionally substituted”.

[0045] The term “alkylthio” as used herein means a thio group with one alkyl substituent (i.e., —S—alkyl), where alkyl is defined as above.

[0046] The term “amino” as used herein means a moiety represented by the structure NR , and includes primary amines, and secondary and tertiary amines substituted by alkyl (i.e., alkylamino). Thus, R²³ may represent, for example, two hydrogen atoms, two alkyl moieties, or one hydrogen atom and one alkyl moiety.

[0047] The term “aryl” refers to a monocyclic, bicyclic, tricyclic or other polycyclic carbon ring of up to 8 members in each ring, wherein at least one ring is aromatic as defined by the Huckel 4n+2 rule. The term includes polycyclic systems comprising saturated carbon rings or heteroaryl or heterocyclic groups so long as at least one ring is aryl, as described. An “arylene” group is similarly defined as a divalent aryl group.

[0048] The terms aralkyl and arylalkyl as used herein mean an aryl group as defined above linked to the molecule through an alkylene group as defined above.

[0049] For the purposes of the present invention, where a combination of groups is referred to as one moiety, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule. A typical example of an arylalkyl group is benzyl.

WO 2017/140778

PCT/EP2017/053498 [0050] The term “heteroaryl” refers to an aryl group containing from one or more (particularly one to four) non-carbon ring atom(s) (particularly N, O or S) or a combination thereof. A heteroaryl group may be optionally substituted at one or more carbon or nitrogen atom(s). Heteroaryl rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings. Heteroaryl includes, but is not limited to, 5-membered heteroaryls having one hetero atom (e.g., thiophenes, pyrroles, furans); 5-membered heteroaryls having two heteroatoms in 1,2 or 1,3 positions (e.g., oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-membered heteroaryls having three heteroatoms (e.g., triazoles, thiadiazoles); 5-membered heteroaryls having four heteroatoms (e.g., tetrazoles); 6-membered heteroaryls with one heteroatom (e.g., pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine); 6-membered heteroaryls with two heteroatoms (e.g., pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines); 6-membered heteroaryls with three heteroatoms (e.g., 1,3,5- triazine); and 6-membered heteroaryls with four heteroatoms. “Substituted heteroaryl” means a heteroaryl having one or more groups as substituents and including those defined under “optionally substituted”. A “heteroarylene” group is similarly defined as a divalent heteroaryl group.

[0051 ] Heterocyclyl as used herein refers to a non-aromatic ring having 3 to 8 atoms in the ring, preferably 5 to 8 atoms in the ring, and of those atoms 1 to 4 are heteroatoms (particularly N, O or S). Heterocyclic rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings. Heterocyclic includes partially and fully saturated heterocyclic groups. Heterocyclic systems may be attached to another moiety via any number of carbon atoms or heteroatoms of the radical and may be both saturated and unsaturated. Non-limiting examples of heterocyclic groups include C₄-C₆selenocycles, pyrrolidinyl, pyrrolinyl, pyranyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolinyl, dithiolyl,

WO 2017/140778

PCT/EP2017/053498 oxathiolyl, dioxanyl, dioxinyl, oxazinyl, azepinyl, diazepinyl, thiazepinyl, oxepinyl and thiapinyl, imidazolinyl, thiomorpholinyl, and the like.

[0052] The term “acyl” as used herein means C(O)R¹⁹ wherein R¹⁹ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl or heterocyclyl. [0053] The term “halo” as used herein refers to fluoro, chloro, bromo and iodo groups. Similarly the term “halogen” as used herein refers to fluorine, chlorine, bromine and iodine.

[0054] Optionally substituted” in reference to a substituent group refers to substituent groups optionally substituted with one or more moieties, for example, those selected from the group consisting of optionally substituted Ci-1₀alkyl (e.g., optionally substituted Ci_₆ alkyl); optionally substituted C₃.₆ cycloalkyl (e.g., optionally substituted cyclopropyl), optionally substituted hydroxylalkyl; optionally substituted C1-10 alkoxy (e.g., optionally substituted Ci_₆ alkoxy); optionally substituted C₂-ioalkenyl; optionally substituted C2-10 alkynyl; optionally substituted C₆-i₂ aryl; aryloxy; optionally substituted heteroaryl; optionally substituted heterocyclyl; halo (e.g., Cl, F, Br, and I); hydroxyl; halogenated alkyl (e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂CF₃, and CF₂CF₃); amino (e.g., NH₂, NR²⁴H, and NR²⁴R²⁵); alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR²⁴R²⁵; CO2R²⁴; CH2OR²⁴; NHCOR²⁴; NHCO2R²⁴; Ci_3 alkylthio; sulfate; sulfonic acid; sulfonate esters such as alkyl or aralkyl sulfonyl, including methanesulfonyl; phosphonic acid; phosphate; phosphonate; mono-, di-, or triphosphate esters; trityl or monomethoxytrityl; R²⁴SO; R²⁴SO2; CF₃S; and CF₃SO₂; trialkylsilyl such as dimethyl-t-butylsilyl or diphenylmethylsilyl; and R²⁴and R²⁵ are each independently selected from H or optionally substituted C1-1₀alkyl, Ci_₆ alkyl or Ci_₄ alkyl. Optional substituents also include cyclic structures such as cyclic hydrocarbon (e.g. cycloalkyl, cycloalkenyl), heterocyclic, aryl and heteroaryl rings, fused to the parent moiety.

[0055] Whenever a range of the number of atoms in a structure is indicated (e.g., a Ci-Ci₂, C1-C10, C1-C9, Οι-Οθ, Ci-C₄, or C₂-C₂q, C₂-Ci₂, C₂-Ciq, C₂-Cg,

WO 2017/140778

PCT/EP2017/053498

C₂-C₈, C₂-C₆, C₂-C₄ alkyl, alkenyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1-12 carbon atoms (e.g., Ci-Ci₂), 1-9 carbon atoms (e.g., C1-C9), 1-6 carbon atoms (e.g., Ci-C₆), 1 -4 carbon atoms (e.g., C1-C4), 1 -3 carbon atoms (e.g., C1-C3), or

2-8 carbon atoms (e.g., C₂-C₈) as used with respect to any chemical group (e.g., alkyl, etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11, and/or 12 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 1 -9 carbon atoms, 1 -10 carbon atoms, 1 -11 carbon atoms, 1 -12 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8 carbon atoms, 2-9 carbon atoms, 2-10 carbon atoms, 2-11 carbon atoms, 2-12 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 3-7 carbon atoms, 3-8 carbon atoms, 3-9 carbon atoms, 3-10 carbon atoms, 3-11 carbon atoms, 3-12 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7 carbon atoms, 4-8 carbon atoms, 4-9 carbon atoms, 4-10 carbon atoms, 4-11 carbon atoms, and/or 4-12 carbon atoms, etc., as appropriate).

[0056] According to a first aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

Formula (I) wherein Q is selected from O, S and Se;

J is S or Se;

WO 2017/140778

PCT/EP2017/053498

W¹ and W², when present, are independently selected from N and C;

R¹ and R² are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C₂-Ci₂ alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W¹ and W² is present and is a nitrogen atom and when R¹ or R² are cyclic then the respective W¹ or W² may form part of the ring structure.

[0057] It will be apparent to the skilled addressee that the structure of formula (I) covers compounds wherein either W¹ or W² is nitrogen as well as compounds wherein both W¹ and W² are nitrogen. Additionally, when W¹ and/or W² is nitrogen then that nitrogen may be part of a chain linking to R¹ or R² or may be an atom which forms part of a ring structure.

[0058] In preferred embodiments, R¹W¹- is (R¹)2N- or (R¹)HN- or (R¹)-, and -W²R² is -N(R²)2 or -NH(R²) or -(R²), provided that a nitrogen atom of R¹W¹- and/or a nitrogen atom of -W²R² is linked to (i.e. bonded to) the remainder of the molecule.

[0059] In one embodiment, a sp³ hybridised nitrogen atom of R¹W¹- is linked to J.

[0060] In another embodiment, a sp³ hybridised nitrogen atom of -W²R² is linked to the remainder of the molecule of formula (I).

[0061] In preferred embodiments, Q is O and J is S.

[0062] In one embodiment, R¹ and R² are independently Ci-C10alkyl which may be optionally substituted.

[0063] In an embodiment, R¹ and R² are independently Ci-C₈ alkyl which may be optionally substituted.

WO 2017/140778

PCT/EP2017/053498 [0064] In a further embodiment, R¹ and R² are independently Ci-C₆ alkyl which may be optionally substituted.

[0065] In one embodiment, R¹ and R² are independently C1-C10 alkenyl which may be optionally substituted.

[0066] In a further embodiment, R¹ and R² are independently Ci-C₈alkenyl which may be optionally substituted.

[0067] In an embodiment, R¹ and R² are independently Ci-C₆ alkenyl which may be optionally substituted.

[0068] In one embodiment, R¹ and R² are independently C1-C10 alkynyl which may be optionally substituted.

[0069] In a further embodiment, R¹ and R² are independently Ci-C₈alkynyl which may be optionally substituted.

[0070] In one embodiment, R¹ and R² are independently Ci-C₆alkynyl which may be optionally substituted.

[0071] In an embodiment, one or more hydrogens of the alkyl, alkenyl or alkynyl groups is deuterated.

[0072] In certain embodiments, R¹ and R² are independently C₃-C₈cycloalkyl or cycloalkenyl which may each be optionally substituted.

[0073] In one embodiment, R¹ and R² are independently C4-C7cycloalkyl or cycloalkenyl which may each be optionally substituted.

[0074] In one embodiment, R¹ and R² are independently selected from C₅ or C₆ cycloalkyl or cycloalkenyl, each of which may be optionally substituted.

[0075] In one embodiment, R¹ and R² are independently C₆-C₈aryl which may be optionally substituted.

[0076] In one embodiment, R¹ and R² are independently C₆-C₇aryl which may be optionally substituted.

WO 2017/140778

PCT/EP2017/053498 [0077] In one embodiment, W² and R² may form an indacene group, including substituted, for example halogenated, and hydrogenated variants thereof.

[0078] In one embodiment, W² and R² may form a hexahydro-indacene group, preferably a hexahydro-s-indacene group.

[0079] In one embodiment, R¹ and R² are independently C₅-C₈ heteroaryl which may be optionally substituted.

[0080] In one embodiment, R¹ and R² are independently C₅-C₇ heteroaryl which may be optionally substituted.

[0081 ] In one embodiment, R¹ and R² are independently selected from C₅ or C₆ heteroaryl, each of which may be optionally substituted.

[0082] In one embodiment, R¹ and R² are independently C₃-C₈ heterocyclyl which may be optionally substituted.

[0083] In one embodiment, R¹ and R² are independently C4-C7 heterocyclyl which may be optionally substituted.

[0084] In one embodiment, R¹ and R² are independently selected from C₅ or C₆ heterocyclyl, each of which may be optionally substituted.

[0085] It will be understood that W¹ and W² may independently represent -N- or -NH depending on the degree of substitution with R¹. That is, when R¹is, for example, C3 alkyl then W¹ may either be mono- or disubstituted with C3 alkyl. Thus in all definitions where R¹ or R² are described as e.g. alkyl, alkenyl etc. then this may also be read as dialkyl, dialkenyl etc.

[0086] In one embodiment W¹/R¹ or W²/R² may form a selenocycle.

[0087] In one embodiment -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions, wherein

-W²R² may optionally be further substituted. For example, -W²R² may be a phenyl group substituted at the 2- and 6-positions. Typical substituents at the a

WO 2017/140778

PCT/EP2017/053498 and a' positions include alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, cycloalkenyl, alkynyl, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, heterocyclyl, arylalkyl and heteroarylalkyl groups. More typically, the substituents at the a and a' positions are independently selected from alkyl and cycloalkyl groups, such as C₃-C₆ branched or C₃-C₆ cyclic alkyl groups, e.g. isopropyl, cyclopropyl, cyclohexyl or t-butyl groups. Other typical substituents at the a and a' positions include cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings which are fused to the parent aryl or heteroaryl group across the α,β and/or α',β' positions respectively. Such fused aryl and fused heteroaryl groups are described in greater detail below.

[0088] As used herein, the nomenclature α, β, a', β' refers to the position of the atoms of the aryl or heteroaryl group relative to the point of attachment of the -W²R² moiety to the remainder of the molecule. For example, where -W²R²is a 1,2,3,5,6,7-hexahydro-s-indacen-4-yl moiety, the α, β, a' and β' positions are as follows:

[0089] In one embodiment -W²R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl group is fused to one or more cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings, wherein -W²R² may be optionally substituted.

[0090] In another embodiment, -W²R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl group is fused to two or more cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings, wherein -W²R² may be

WO 2017/140778

PCT/EP2017/053498 optionally substituted. Typically, the two or more cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings are each ortho-fused to the aryl or heteroaryl group, i.e. each fused cyclic hydrocarbon, heterocyclic, aryl or heteroaryl ring has only two atoms and one bond in common with the aryl or heteroaryl group.

[0091] In yet another embodiment, -W²R² is a fused aryl or a fused heteroaryl group, wherein a first cyclic hydrocarbon, heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α,β positions and a second cyclic hydrocarbon, heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α',β' positions, and wherein -W²R² may be optionally substituted.

[0092] Typically in any embodiment where -W²R² is a fused aryl or a fused heteroaryl group, R¹W¹- is (R¹)2N- or R¹NH-, J is S and Q is O, wherein R¹ is as previously defined.

[0093] In one embodiment, -W²R² has a formula selected from:

wherein A¹ and A² are each independently selected from an optionally

WO 2017/140778

PCT/EP2017/053498 substituted alkylene or alkenylene group, which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and wherein B¹ is hydrogen or any optional substituent. B¹ and any optional substituent attached to A¹ or A²may together with the atoms to which they are attached form a further fused cyclic hydrocarbon, heterocyclic, aryl or heteroaryl ring which may itself be optionally substituted. Similarly, any optional substituent attached to A¹ and any optional substituent attached to A² may also together with the atoms to which they are attached form a further fused cyclic hydrocarbon, heterocyclic, aryl or heteroaryl ring which may itself be optionally substituted.

[0094] Typically, B¹ is hydrogen or a halo, hydroxyl, -CN, -NO₂, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy group.

[0095] Typically, any ring containing A¹ or A² is a five or a six membered ring.

[0096] In a further embodiment, -W²R² has a formula selected from:

N

J J

WO 2017/140778

PCT/EP2017/053498

[0097] Examples of compounds where -W²R² is a fused aryl or a fused heteroaryl group include the compounds of Examples 1-43 below and the compounds:

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l/-/-indol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-l/-/-indol-6amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

ndacen-44-. .

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)( A/-benzyl-1-(1 -methyl-1 /-/-pyrazol-3yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(AAbenzyl-l-(l-isopropyl-l/-/-pyrazol-3yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(A/-benzyl-1-(1-(2,2,2-trifluoroethyl)-1/-/pyrazol-3-yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/]isoxazol-6amine)sulfonamide /\/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/|isoxazol-5amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methylbenzo[c/]oxazol-6amine) sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4yl)earbamoyl)(2-methylbenzo[cf]oxazol-5amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

/\/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoy l)piperazine-1 -sulfonamide

4-acetyl-A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)piperazine-1 -sulfonamide

4-benzyl-/\/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)piperazine-1 -sulfonamide

iV-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)2,4,6-trimethylpiperazine-1 -sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen-4-yl)carbamoyl)3,4,5-trimethylpiperazine-l-sulfonamide

iV-((l,2,3,5,6,7-hexahydro-s-indacen-4y Ijcarbamoy l)octahydro-2//-py ri do| 1,2-a] py raz i ne-2sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methyl-l/7-benzo[c/|imidazol-6amine)sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4yl)carbamoyl)(l,2-dimethyl-l/-/-benzo[c/|imidazol-6amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(benzo[d][l,2,3]oxadiazol-6amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-l/-/benzo[<i|[l,2,3]triazol-5-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-l/-/benzo[c/|[l,2,3]triazol-6-amme)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(l/-/-indazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(l/-/-indazol-5-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(l-methyl-l/-/-indazol-5amine)sulfonamide

7V-((l,2,3,5,6,7-hexahydro-s-indacen4-yl)carbamoyl)-3,5dimethylmorpholine-4-sulfonamide

7V-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)-2,6-dimethylmorpholine4-sulfonamide

lV-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)piperidine-l-sulfonamide

7V-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)-4-methylpiperidine-l-sulfonamide

7V-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)-2,4,6-trimethylpiperidine-1 sulfonamide

WO 2017/140778

PCT/EP2017/053498

7V-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)-3,4,5-trimethylpiperidine-lsulfonamide

A?-((l,2,3,5,6,7-hexahydro-5-indacen-4yl)carbamoyl)-4-hydroxypiperidine-1 sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4yl)carbamoyl)(6-methoxypyridin-3amino)sulfonamide

/V-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methoxypyrimidin-5amino)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(6-methoxypyridazin-3amino)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(5-methoxypyrazin-2amino)sulfonamide [0098] In one embodiment, R¹W¹- comprises a heteroaryl group, wherein R¹W¹- may be optionally substituted. Typically in any embodiment where R¹W¹comprises a heteroaryl group, a nitrogen atom of R¹ W¹- is linked to J. Typically, in any embodiment where R¹ W¹- comprises a heteroaryl group and a nitrogen atom of R¹W¹- is linked to J, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in any embodiment where R¹W¹- comprises a heteroaryl group, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions. More typically, in any embodiment where R¹W¹- comprises a heteroaryl group, a nitrogen atom of R¹W¹- is linked to J and -W²R² is an aryl group, wherein the aryl group is substituted at the a and a' positions and optionally at other positions.

WO 2017/140778

PCT/EP2017/053498 [0099] In one embodiment, R¹W¹- is R¹NH- or (R¹)₂N- wherein at least one

R¹ comprises a heteroaryl group, or two R¹ together with the nitrogen atom to which they are attached form a heteroaryl group or a cyclic group which is substituted with a heteroaryl group, wherein R¹W¹- may be optionally substituted.

[00100] In one embodiment, R¹W¹- is Het-L-NH- or Het-L-NR¹-, wherein Het is an optionally substituted heteroaryl group, -L- is a bond or an optionally substituted alkylene, alkenylene, alkynylene or arylene group, which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and R¹ is as previously defined. Typically, -L- is a bond or a Ci-C₂ alkylene group.

[00101] In one embodiment, Het is an optionally substituted monocyclic or bicyclic heteroaryl group. Typically, such a group is unsubstituted or substituted with one or more halo, alkyl, alkoxy, aryl, alkylaryl, alkoxyaryl, heteroaryl or halogenated alkyl groups.

[00102] In a further embodiment, Het is selected from an optionally substituted furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl or pteridinyl group. Typically, such a group is unsubstituted or substituted with one or more halo, alkyl, alkoxy, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, arylalkyl, heteroarylalkyl, or halogenated alkyl groups.

[00103] Examples of compounds where R¹W¹- comprises a heteroaryl group include the compounds of Examples 4, 8,13, 14,15, 17-23, 27, 29, 30, 35, 39, 42 and 43 below and the compounds:

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l/7-indol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 H-i ndol-6-ami ncjsu I lonamidc

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)( 1 -methyl-1 /-/-indol-6amine) sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indol-6-amine)sulfonamide

/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /7-indol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

/\/-((2,6-diisopropylphenyl)carbamoyl) (1 /7-indol-5-amine)sulfonamide

/V-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /7-indol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 /7-indol-5-amine)sulfonamide

Λ/-((1,2,3,5,6,7-hexahydro-S-indacen-4. _uyl)carbamovT)(l-n^thyl1 H-i ndol-5-airfi ne )su I lonftmide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /7-indol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /7-indol-5-amine) sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /7-indol-5-amine) sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(thiazol-2-yl)methanamine)sulfonamide

J

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(thiazol-2-yl)methanamine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(thiazol-2-yl)methanamine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (AAbenzyl-1-( 1-methyl-1 H-pyrazol-3-y 1)methanaminejsulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(A/-benzyl-1 -(1-methyl-1 /-/-pyrazol-3yl)methanamine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(l-methyl-lH-pyrazol-3-yl)methanamine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl- l-(l-methyl-l H-pyrazol-3-yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(A/-benzyl-l-(l-isopropyl-l/-/-pyrazol-3yl)methanamine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(l-isopropyl-l/-/-pyrazol-3-yl)methanamine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-1 -(1-isopropyl-1 /-/-pyrazol-3-yl)methanamine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-l-(l-isopropyl-l/-/-pyrazol-3-yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(/\/-benzyl-1-(1-(2,2,2-trifluoroethyl)-1/-/pyrazol-3-yl)methanamine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-1-(1-(2,2,2-trifluoroethy 1)-1 /7-pyrazol-3-yl)methanamine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-1-(1 -(2,2,2-trifluoroethyl)-1 H-pyrazol-3-yl)methanamine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (A/-benzyl-1-(1-(2,2,2-trifluoroethyl)-1 H-pyrazol-3-yl)methanamine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/|isoxazol-6amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/|isoxazol-6-amine)sulfonamide

J

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[cf|isoxazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[cf|isoxazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/|isoxazol-5amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/|isoxazol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/|isoxazol-5-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/|isoxazol-5-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methylbenzo[c/|oxazol-6amine) sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-6-amine)sulfonamide

J

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-6-amine)sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4yl)carbamoyl)(2-methylbenzo[c/|oxazol-5amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-5-amine)sulfonamide

/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-5-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-5-amine)sulfonatnide

/V-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methyl-l/7-benzo[c/|imidazol-6amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (2-methyl-1 /-/-benzo[c/|imidazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methyl-l/-/-benzo[c/|imidazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (2-methyl-l/-/-benzo[c/|imidazol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (l,2-dimethyl-l/-/-benzo[c/|imidazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1,2-dimethyl-1 /-/-benzo[ c/|imidazol-6amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (l,2-dimethyl-l/-/-benzo[c/|imidazol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (benzo[ci|[l,2,3]oxadiazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (benzo[c/|[l,2,3]oxadiazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (benzo[c/|[l,2,3]oxadiazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-l/-/benzo[0][l,2,3]triazol-5-amme)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-benzo[c/|[l,2,3]triazol-5-ainine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-benzo[c/|[l,2,3]triazol-5amine) sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-benzo[cf|[l,2,3]triazol-5-amine)sulfonamide

J J

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-benzo[c/| [1,2,3]triazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-benzo[c/|[l,2,3]triazol-6amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-benzo[ c/| [1,2,3] triazol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1-methyl-1 /-/-indazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indazol-6-amine)sulfonamide

N^NH / \

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4-yl)carbamoyl)(l/-/-indazol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /7-indazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(l/7-indazoi-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-5-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-5-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 H-indazol-5-ami ncjsu I lonamidc

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /7-indazol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indazol-5-amine) sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-indazol-5-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (6-methoxy-4-methylpyridin-3-amino)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (6-methoxy-4-methylpyridin-3-amino)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (6methoxy-4-methylpyridin-3-amino)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridin-3-amino)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridin-3-amino)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridin-3-amino)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(2-methoxypyrimidin-5amino)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (2-methoxypyrimidin-5-amino)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methoxypyrimidin-5-amino)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (2-methoxypyrimidin-5-amino)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridazin-3-ammo)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridazin-3-amino)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (6-methoxypyridazin-3-amino)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(5-methoxypyrazin-2amino)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (5-methoxypyrazin-2-amino)sulfonamide

/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (5-methoxypyrazin-2-amino)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (5-methoxypyrazin-2-amino)sulfonamide

WO 2017/140778

PCT/EP2017/053498 [00104] In one embodiment, R¹W¹- comprises a heterocyclic group containing a nitrogen atom and at least one further heteroatom in the heterocyclic ring, wherein R¹W¹- may be optionally substituted. For example, R¹W¹- may comprise a heterocyclic group containing at least two nitrogen atoms in the heterocyclic ring, wherein R¹W¹- may be optionally substituted. Typically in any embodiment where R¹W¹- comprises a heterocyclic group containing a nitrogen atom and at least one further heteroatom in the heterocyclic ring, a nitrogen atom of R¹W¹- is linked to J, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in any embodiment where R¹ W¹- comprises a heterocyclic group containing a nitrogen atom and at least one further heteroatom, such as a nitrogen atom, in the heterocyclic ring, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions.

[00105] In one embodiment, R¹W¹- is (R¹)2N- wherein both R¹ and the nitrogen atom to which they are attached together form an optionally substituted heterocyclic group containing at least one further heteroatom N, O or S in the heterocyclic ring. Typically, R¹W¹- is (R¹)2N- wherein both R¹ and the nitrogen atom to which they are attached together form an optionally substituted heterocyclic group containing at least one further nitrogen atom in the heterocyclic ring. Typically, the heterocyclic group is monocyclic or bicyclic.

[00106] In one embodiment, R¹W¹- is (R¹)2N-, wherein (R¹)2N- is an optionally substituted piperazinyl, morpholinyl or thiomorpholinyl group. Typically such a group is unsubstituted or substituted with one or more halo, alkyl, alkoxy, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, arylalkyl, heteroarylalkyl, or halogenated alkyl groups.

[00107] Examples of compounds where R¹W¹- comprises a heterocyclic group containing a nitrogen atom and at least one further heteroatom in the heterocyclic ring include the compounds of Examples 1,2, 13, 16, 17 and 41 below and the compounds:

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoy l)piperazine-1 -sulfonamide

iV-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)2,4,6-trimethylpiperazine-1 -sulfonamide iV-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)3,4,5-trimethylpiperazine-l-sulfonamide

iV-((l,2,3,5,6,7-hexahydro-s-indacen-4y I (carbamoyl )octahydro-2//-pyri do| 1,2-a]pyrazine-2sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-piperazine- 1-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-piperazine- 1-sulfonamide

A/-((4-fluoro-2,6diisopropylphenyl)carbamoyl)piperazine- 1-sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

N-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-4-(2,2,2trifluoroethyl)piperazine-l-sulfonamide

4-acetyl-A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-piperazine-1 -sulfonamide

4-acetyl-/\/-((2,6-diisopropylphenyl)carbamoyl)

-piperazine-1 -sulfonamide

4-acetyl-A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)

-piperazine- 1-sulfonamide

4-benzyl-A/-((2,6-diisopropylphenyl)carbamoyl) -piperazine-1 -sulfonamide

4-benzyl-/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) -piperazine- 1-sulfonamide

4-benzyl-/\/-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-piperazine-lsulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperazine- 1-sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperazine-l-sulfonamide

Al-((4-fluoro-2,6-diisopropylphenyl)-carbamoyl)2,4,6-trimethylpiperazine-l-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-3,4,5-trimethylpiperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-3,4,5-trimethylpiperazine-1 -sulfonamide

iV-((4-fluoro-2,6-diisopropylphenyl)-carbamoyl)3,4,5-trimethylpiperazine-l-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)octahydro-2/-/-pyrido[l,2-a]pyrazine-2-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-octahydro-2/-/-pyrido[l,2-a]pyrazine-2-sulfonamide

7V-((4-fluoro-2,6-diisopropylphenyl)carbamoy I )octahydro-2//-py ri do [1,2a]pyrazine-2-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-morpholine-4-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-morpholine-4-sulfonamide

WO 2017/140778

PCT/EP2017/053498

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)morpholine4-sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen4-yl)carbamoyl)-3,5dimethylmorpholine-4-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-3,5-dimethylmorpholine-4-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-3,5-dimethylmorpholine-4-sulfonamide

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-3,5dimethylmorpholine-4-sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen-4yl)carbamoyl)-2,6-dimethylmorpholine4-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-2,6-dimethylmorpholine-4-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-2,6-dimethylmorpholine-4-sulfonamide

WO 2017/140778

PCT/EP2017/053498

7V-((4-fhioro-2,6diisopropylphenyl)carbamoyl)-2,6dimethylmorpholine-4-sulfonamide [00108] In one embodiment, R¹W¹- is R¹NH- or (R¹)2N-wherein at least one R¹ comprises a fused bicyclic group, or two R¹ together with the nitrogen atom to which they are attached form a fused bicyclic group, wherein R¹W¹- may be optionally substituted. The fused bicyclic group may be optionally substituted and may be carbocyclic or heterocyclic. Both rings of the bicyclic group may be aromatic, or one ring may be aromatic and the other non-aromatic, or both rings may be non-aromatic. Typically in any embodiment where R¹W¹- is R¹NH- or (R¹)2N- wherein at least one R¹ comprises a fused bicyclic group, or two R¹together with the nitrogen atom to which they are attached form a fused bicyclic group, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in any embodiment where R¹W¹- is R¹NH- or (R¹)₂N- wherein at least one R¹ comprises a fused bicyclic group, or two R¹ together with the nitrogen atom to which they are attached form a fused bicyclic group, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions.

[00109] In one embodiment, R¹W¹- is Bic-L-NH- or Bic-L-NR¹-, wherein Bic is an optionally substituted fused bicyclic group, -L- is a bond or an optionally substituted alkylene, alkenylene, alkynylene or arylene group, which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and R¹ is as previously defined. Typically, -L- is a bond or a Ci-C₂ alkylene group.

[00110] In one embodiment, Bic comprises a 5-membered ring fused to a sixmembered ring. Typically in such an embodiment, the six-membered ring is

WO 2017/140778

PCT/EP2017/053498 aromatic. Examples of such groups include optionally substituted indolyl, isoindolyl, indolinyl, indazolyl, indenyl, indanyl and 1,3-benzodioxolyl groups. [00111] Examples of compounds where R¹W¹- is R¹NH- or (R¹)₂N-wherein at least one R¹ comprises a fused bicyclic group, or two R¹ together with the nitrogen atom to which they are attached form a fused bicyclic group, include the compounds of Examples 8, 28, 34, 36, 37, 38,40,42 and 43 below and the compounds:

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 H-i ndol-6-ami nc)su I lonamidc

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1H- i ndol-6-am i ncjsu I lonam ide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-5-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indol-5-amine)sulfonamide

ndaccn-4imide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indol-5-amine) sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/]isoxazol-6amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/]isoxazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/]isoxazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/]isoxazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(3-methylbenzo[c/]isoxazol-5amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (3-methylbenzo[c/]isoxazol-5-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-5-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (2-methylbenzo[c/|oxazol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-octahydro-2/-/-pyrido[l,2-a]pyrazine-2-sulfonamide

W-((4-fluoro-2,6-diisopropylphenyl)carbamoy I )octahydro-2//-py ri do [1,2a]pyrazine-2-sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)earbamoyl)(2-methyl-l/-/-benzo[c/|imidazol-6amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (2-methyl-1 /-/-benzo[ c/| i midazol-6-ami ne)sul fonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (2-methyl-l/-/-benzo[c/|imidazol-6-amine)sulfonami de

WO 2017/140778

PCT/EP2017/053498

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4yl)carbamoyl)( 1,2-dimethyl-1 H-benzo [ <5| i m idazol -6amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (l,2-dimethyl-lH-benzo[d|imidazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1,2-dimethyl-1 H-benzo[ <5|imidazol-6amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (l,2-dimethyl-lH-benzo[d|imidazol-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (benzo[cf|[l,2,3]oxadiazol-6-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (benzo[cf|[l,2,3]oxadiazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (benzo[cf|[l,2,3]oxadiazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-lHbenzo[<i|[l,2,3]triazol-5-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1-methyl-lH-benzo[c/|[l,2,3]triazol-5-amine)sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-benzo[c/][l,2,3]triazol-5amine) sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) ( I-methyl-1 /“/-bcnzo| d|| 1.2.3 |triazol-5-ami nc)suIlonamidc

J J

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4yl)carbamoyl)(l-methyl-lHbcnzo| c/|| 1.2.3 |triazol-6-aminc)sul lonamidc

A/-((2,6-diisopropylphenyl)carbamoyl) ( I-methyl-1 /“/-benzo| c/|| 1.2.3 |triazol-6-ami nejsullonamide

/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 H-benzo | c/| [ 1,2,3] triazol-6amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 H-ben zo| c/| [1,2,3] triazol-6-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 H-i ndazo l-6-am i n e )su I lonami de

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-mdazol-6-amine)sulfonamide

Λ/-(( 1,2,3,5,6,7-hexahydro- S-indacen-4-yl)carbamoyl)(l/-/-indazoi-6-amine)sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-6-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (1 /-/-indazol-6-amine)sulfonamide

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(l/-/-indazoi-5-amine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((2,6-diisopropylphenyl)carbamoyl) (1 H-i ndazol-5-ami ncjsul lonamidc

A/-((2,6-diisopropylphenyl)carbamoyl) (1 -methyl-1 /-/-indazol-5-amine)sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (l-methyl-l/-/-indazol-5-amine)sulfonamide [00112] In one embodiment, R¹ W¹- is halo-substituted. Typically in such an embodiment, R¹ W¹- is substituted with one or more fluoro and/or chloro groups. Typically in any embodiment where R¹W¹- is halo-substituted, a nitrogen atom of R¹W¹- is linked to J, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in any embodiment where R¹W¹- is halo

WO 2017/140778

PCT/EP2017/053498 substituted, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions.

[00113] In one embodiment, R¹W¹- is Har-L-NH- or Har-L-NR¹-, wherein Har is an aryl or a heteroaryl group substituted with one or more halo, halogenated alkyl or halogenated alkoxy groups, wherein Har may optionally be further substituted, -L- is a bond or an optionally substituted alkylene, alkenylene, alkynylene or arylene group, which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and R¹ is as previously defined. Typically, -L- is a bond, a -O-(Ci-C₂ alkylene)- group or a CrC₂ alkylene group.

[00114] In one embodiment, Har is a phenyl or toluyl group substituted with one or more chloro, fluoro, trifluoromethyl and/or trifluoromethoxy groups.

[00115] Examples of compounds where R¹ W¹- is halo-substituted include the compounds of Examples 5, 6, 9-11 and 32 below and the compounds:

/V-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)(/V-benzyl-1-(1-(2,2,2-trifluoroethyl)-1/7pyrazol-3-yl)methanamine)sulfonamide

/V-((2,6-diisopropylphenyl)carbamoyl) (/V-benzyl-1-(1-(2,2,2-trifluoroethy 1)-l/7-pyrazol-3-yl)methanamine)sulfonamide

/V-((4-chloro-2,6-diisopropylphenyl)carbamoyl) (/V-benzyl-1-(1 -(2,2,2-trifluoroethyl)-l/7-pyrazol-3-yl)methanamine)sulfonamide

/V-((4-fluoro-2,6-diisopropylphenyl)carbamoyl) (/V-benzyl-1-(1-(2,2,2-trifluoroethyl)-1/7-pyrazol-3-yl)methanamine)sulfonamide

WO 2017/140778

PCT/EP2017/053498

A/-((l,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4(2,2,2-trifluoroethyl)piperazine-1 -sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

A/-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-4-(2,2,2trifluoroethyl)piperazine-1 -sulfonamide [00116] In one embodiment, R¹W¹- is Het-X-(CH2)m-NH-, Ar-X-(CH2)m-NH-, Het-X-(CH2)m-NR¹- or Ar-X-(CH2)_m-NR¹-; wherein Het is as defined above; Ar is an optionally substituted aryl group; -X- is a bond, - NH-, -S- or -O-; and m is

2-6. Typically m is 2-4. More typically m is 2. Typically in such an embodiment, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in such an embodiment, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions. Examples of compounds where R¹W¹- is Het-X-(CH2)m-NH-, Ar-X-(CH2)m-NH-, Het-X-(CH2)m-NR¹- or Ar-X-(CH2)_m-NR¹- include the compounds of Examples 5, 15, 21 and 24-26 below.

[00117] In one embodiment, R¹ W¹- is substituted with an alkylsulphonyl or a cyano group. For example, R¹W¹- may be R¹NH- or (R¹)2N- wherein at least one R¹ is a cyano- or alkylsulphonyl-substituted aryl or arylalkyl group, which may optionally be substituted with further substituents. Typically in such an embodiment, a nitrogen atom of R¹W¹- is linked to J, J is S, Q is O and -W²R²is -R² wherein R2 is as previously defined. Typically in such an embodiment, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions.

WO 2017/140778

PCT/EP2017/053498

Examples of compounds where R¹ W¹- is substituted with an alkylsulphonyl or a cyano group include the compounds of Examples 7 and 33 below.

[00118] In one embodiment, R¹W¹- is R¹N(Me)-, wherein R¹ is an optionally substituted aryl or heteroaryl group. Typically in such an embodiment, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in such an embodiment, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions. An example of such a compound is the compound of Example 31 below.

[00119] In one embodiment, R¹W¹- is Am-M-NH- or Am-M-NR¹-, wherein Am is a primary, secondary or tertiary amino group, -M- is a branched alkylene, a cycloalkylene or a cycloalkyl-substituted alkylene group, and R¹ is as previously defined. Typically, Am is a dialkylamino group and -M- is a cycloalkylsubstituted alkylene group. Typically in such an embodiment, J is S, Q is O and -W²R² is -R² wherein R² is as previously defined. Typically in such an embodiment, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions. An example of such a compound is the compound of Example 12 below.

[00120] In one embodiment, R¹W¹- comprises a heterocyclic group, wherein the heterocyclic group is substituted with one or more hydroxyl, halo, alkyl, alkoxy, halogenated alkyl or halogenated alkoxy groups. Optionally the substituted heterocyclic group contains a single heteroatom in the heterocyclic ring, such as nitrogen. Alternatively the substituted heterocyclic group may contain two or more heteroatoms in the heterocyclic ring, such as nitrogen and one or more further heteroatoms selected from Ο, N or S. Typically, the substituted heterocyclic group is substituted with one or more hydroxyl or C1-C4 alkyl groups. Typically in any embodiment where R¹W¹-comprises a substituted heterocyclic group, a nitrogen atom of R¹W¹- is linked to J. Typically, in any embodiment where R¹W¹- comprises a substituted heterocyclic group and a

WO 2017/140778

PCT/EP2017/053498 nitrogen atom of R¹W¹- is linked to J, J is S, Q is O and -W²R² is -R² wherein R²is as previously defined. Typically, in any embodiment where R¹ W¹- comprises a substituted heterocyclic group, -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions. Specific examples of such compounds include the compounds of Examples 2 and 41 below and:

/\/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-4-methylpiperidine-1 -sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-4-methylpiperidine-1-sulfonamide

diisopropylphenyl)carbamoy 1)-4methylpiperidine-1 -sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen-4yl)carbamoy l)-2,4,6-trimethylpiperidine-1 sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperidine-1-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperidine- 1-sulfonamide

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-2,4,6trimethylpiperidine- 1-sulfonamide

WO 2017/140778

PCT/EP2017/053498

iV-((l,2,3,5,6,7-hexahydro-s-indacen-4yl)carbamoyl)-3,4,5-trimethylpiperidine-lsulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-3,4,5-trimethylpiperidine-l-sulfonamide

N-((2,6-diisopropylphenyl)carbamoyl)

-3,4,5-trimethylpiperidine-1 -sulfonamide

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-3,4,5trimethy lpiperidine-1 - sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen-4yl)carbamoyl)-4-hydroxypiperidine-1 sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-4-hydroxypiperidine-1 -sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-4-hydroxypiperidine-1 -sulfonamide

A/-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)

-4-hydroxypiperidine-1 - sulfonamide

Ai-((l,2,3,5,6,7-hexahydro-5-indacen-4-yl)carbamoyl)2,4,6-trimethylpiperazine-l-sulfonamide

WO 2017/140778

PCT/EP2017/053498

A7-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)3,4,5-trimethylpiperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-4-(2,2,2-trifluoroethyl)piperazine-l-sulfonamide

A/-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-4-(2,2,2trifluoroethyl)piperazine-l-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-2,4,6-trimethylpiperazine-l-sulfonamide

A?-((4-fluoro-2,6-diisopropylphenyl)-carbamoyl)2,4,6-trimethylpiperazine-l-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl) -3,4,5-trimethylpiperazine-l-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-3,4,5-trimethylpiperazine-l-sulfonamide

Ai-((4-fluoro-2,6-diisopropylphenyl)-carbamoyl)3,4,5-trimethylpiperazine-l-sulfonamide

WO 2017/140778

PCT/EP2017/053498

/V-((l,2,3,5,6,7-hexahydro-s-indacen4-yl)carbamoyl)-3,5dimethylmorpholine-4-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-3,5-dimethylmorpholine-4-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-3,5-dimethylmorpholine-4-sulfonamide

A/-((l,2,3,5,6,7-hexahydro-5-indacen-4yl)carbamoyl)-2,6-dimethylmorpholine4-sulfonamide

A/-((2,6-diisopropylphenyl)carbamoyl)

-2,6-dimethylmorpholine-4-sulfonamide

A/-((4-chloro-2,6-diisopropylphenyl)carbamoyl)

-2,6-dimethylmorpholine-4-sulfonamide

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)-2,6dimethylmorpholine-4-sulfonamide [00121] In one embodiment, when -W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions and optionally at other positions, -W²R² is halo substituted at a position other than the a and a' position of the aryl or the heteroaryl group. For example,

WO 2017/140778

PCT/EP2017/053498

-W²R² may be a phenyl group, wherein the phenyl group is fluoro, chloro and/or bromo substituted at one or more of the 3-, 4- and 5- positions, and substituted at the 2- and 6-positions with groups independently selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, cycloalkenyl, alkynyl, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, heterocyclyl, arylalkyl and heteroarylalkyl groups. Examples of such compounds include:

diisopropylphenyl)carbamoyl)

-piperidine-1 -sulfonamide

7V-((4-fluoro-2,6diisopropylphenyl)carbamoyl)piperidine-1 sulfonamide and [00122] In one embodiment, -W²R² is an optionally substituted -NHR² or -N(R²)₂ group, wherein optionally two R² together with the nitrogen atom to which they are attached may form a cyclic group, and R¹ W¹- is Het, wherein Het is as defined above. Typically in such an embodiment, J is S and Q is O. Typically in such an embodiment, Het is an optionally substituted monocyclic or bicyclic heteroaryl group. More typically, Het is an optionally substituted five membered monocyclic heteroaryl group or an optionally substituted fused bicyclic heteroaryl group containing a five membered and a six membered ring.

[00123] In another embodiment, -W²R² is an optionally substituted -N(R²)₂group, wherein the two R² together with the nitrogen atom to which they are attached form an optionally substituted cyclic aromatic group, such as an optionally substituted pyrrolyl, imidazolyl, pyrazolyl ortriazolyl group. Typically in such an embodiment J is S, Q is O, and R¹W¹- is R¹- wherein R¹ is as previously defined. Typically, the pyrrolyl, imidazolyl, pyrazolyl ortriazolyl group is substituted at least at the 2- and 5-positions, wherein the 2,5-disubstituents are each independently selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, cycloalkenyl, alkynyl, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, heterocyclyl, arylalkyl and heteroarylalkyl groups. More typically, the 2,5WO 2017/140778

PCT/EP2017/053498 disubstituents are each independently selected from alkyl or cycloalkyl groups, such as C₃-C₆ branched or C₃-C₆ cyclic alkyl groups, e.g. isopropyl, cyclopropyl, cyclohexyl or t-butyl groups. Alternatively, -W²R² may be

wherein A¹ and A² are each independently selected from an optionally substituted alkylene or alkenylene group, which may optionally include one or more heteroatoms N, O or S in its carbon skeleton. Typically, each ring containing A¹ or A² is a five or a six membered ring.

[00124] Ina further embodiment, -W²R² has a formula selected from

[00125] Example 4 below is an example of a compound where -W²R² is an optionally substituted -N(R²)₂ group, wherein the two R² together with the nitrogen atom to which they are attached form a cyclic aromatic group.

[00126] In one embodiment, R¹W¹- comprises a heterocyclic group, wherein the heterocyclic group contains a single heteroatom in the heterocyclic ring, such as a nitrogen atom, wherein R¹W¹- may be optionally substituted, and

-W²R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl

WO 2017/140778

PCT/EP2017/053498 group is fused to one or more cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings, wherein -W²R²may be optionally substituted.

[00127] In another embodiment, R¹W¹- comprises a heterocyclic group containing a nitrogen atom and at least one further heteroatom in the heterocyclic ring, wherein R¹W¹- may be optionally substituted, wherein a nitrogen atom of R¹W¹- is linked to J, and wherein -W²R² is a monocyclic aryl or a monocyclic heteroaryl group, wherein the monocyclic aryl or the monocyclic heteroaryl group is substituted at the a and a' positions, wherein the substituents at the a and a' positions are independently selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, cycloalkenyl, alkynyl, acyl, aryl, alkylaryl, alkoxyaryl, heteroaryl, heterocyclyl, arylalkyl and heteroarylalkyl groups, wherein -W²R² may optionally be further substituted.

[00128] In one embodiment of the compound of formula (I), at least one of W¹ and R¹ or W² and R² combine to form a moiety selected from the group consisting of:

— N N—R³

WO 2017/140778

PCT/EP2017/053498

R³

»/vw

</vw

R³ </wv

σννν*

OH wherein, each dashed line may independently be a bond;

T is O or S;

A, B, D, E, W, X, Y and Z, when present, may each be independently selected from O, C(R³), C(R³)₂, N, N(R³) and S;

each incidence of R³ is independently selected from the group consisting of hydrogen, halide, cyano, Ci-C₆ alkyl, Ci-C₆ trifluoroalkyl, Ci-C₆ alkoxy, C=O, SO₂, acyl, amino, hydroxyl, C₅-C₆ heteroaryl, C₅-C₆ heterocyclyl and C₃-C₆cycloalkyl, each of which may be optionally substituted as appropriate; and n is 0, 1,2 or 3.

[00129] It will be appreciated that each ring shown in the above structures with an R³ group extending therefrom indicates that an R³ group may extend from one or more or all of the available positions on said ring for substitution. [00130] Each of these ‘nitrogen-linked’ moieties may be combined with any of the ‘carbon-linked’ moieties described for the compound of the first aspect to form the respective R¹ and R² combination to give the final structure.

[00131 ] In one embodiment, the compound of formula (I) is selected from a compound of formula (II), (III), (IV), (V) or (VI) ora pharmaceutically acceptable salt, solvate or prodrug thereof:

WO 2017/140778

PCT/EP2017/053498

Formula II

Formula III

Formula IV

R¹⁵

R¹⁵

Formula VI wherein W¹ and W², if present, and R¹ and R² are as described in any one or more of the embodiments described for the first aspect;

each incidence of R¹⁵ is independently selected from Ci to C₄ alkyl, Ci to C₄ hydroxylalkyl and C₃ to C₅ cycloalkyl; and

A is optionally substituted heteroaryl or heterocycle, as previously defined, linked to the sulfonyl sulphur through a ring nitrogen.

[00132] In one embodiment of any one of formula II to VI, R¹ or A may be selected from the group consisting of pyrazole, imidazole, triazole, tetrazole,

WO 2017/140778

PCT/EP2017/053498 pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, in one embodiment an indole, each of which may be substituted or unsubstituted.

[00133] In certain embodiments of any one of formula II to VI, R¹ or A may be pyrazole or triazole optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with Ci-C₆ alkyl.

[00134] In one embodiment, R¹⁵ is selected from isopropyl, cyclopropyl and C₃ to C₅ hydroxylalkyl.

[00135] In one embodiment, A is C₃-C₈ heteroaryl or heterocyclyl, each of which may be optionally substituted.

[00136] In one embodiment, A is C₄-C₇ heteroaryl or heterocyclyl, each of which may be optionally substituted.

[00137] In one embodiment, A is selected from C₅ or C₆ heteroaryl or heterocyclyl, each of which may be optionally substituted.

[00138] A may be selected from pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, such as indole, all of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with Ci-C₆ alkyl.

[00139] In one embodiment, the compound of formula (I), (II), (III), (IV) (V) or (VI) is selected from the group consisting of:

WO 2017/140778

PCT/EP2017/053498

OH

WO 2017/140778

PCT/EP2017/053498

WO 2017/140778

PCT/EP2017/053498

[00140] In one embodiment of the first aspect, when J is sulphur, Q is oxo, W² is carbon and R² is cycloalkane, heterocycle or aryl, then R² is not a monocyclic cycloalkane, heterocycle or aryl group.

[00141] In one embodiment of the first aspect, when J is sulphur, Q is oxo, and W² is carbon, then R² is not an alkyl group.

[00142] In one embodiment of the first aspect, when J is sulphur, Q is oxo, and W² is a carbon which is part of a ring system, then R² is not a substituted phenyl group.

WO 2017/140778

PCT/EP2017/053498 [00143] In one embodiment of the first aspect, when J is sulphur, Q is oxo,

W¹ and R¹ together form an alkylamine or dialkylamine and W² is a carbon which is part of a ring system, then R² is not a substituted or unsubstituted phenyl, a tetrahydrobenzothiophene, or other bicyclic thiophene, a pyridine or a pyrimidine group.

[00144] In one embodiment of the first aspect, when J is sulphur, Q is oxo, W¹ is a nitrogen as part of a piperidine or morpholine R¹ group and W² is a carbon which is part of a ring system, then R² is not a pyridine or pyrimidine group.

[00145] In one embodiment of the first aspect, when J is sulphur, Q is oxo, W¹ is a nitrogen as part of a piperidine, piperazine, morpholine, pyrazole, imidazole, pyrrolidine, isoquinoline or thienopyridine R¹ group and W² is a carbon which is part of a ring system, then R² is not a tetrahydrobenzothiophene, or other bicyclic thiophene, or a methyl-substituted pyridine group.

[00146] In one embodiment of the first aspect, when J is sulphur, Q is oxo, W¹ is a nitrogen and W² is a carbon which is part of a ring system, then R² may be an indacene, or substituted or hydrogenated variant thereof, or a phenyl substituted with at least one group selected from halo, C1-C4 alkyl and C₃-C₅cycloalkyl.

[00147] In certain embodiments, the indacene may be a hexahydroindacene and the substituted phenyl group may be selected from 2,6-diisopropyl-4chlorophenyl, 2,6-dicyclopropylphenyl and 2,6-dicyclopropyl-4-chloro-phenyl.

[00148] In one embodiment of the first aspect, when J is sulphur, Q is oxo, W¹ and R¹ together are selected from alkylamine, dialkylamine, arylamine, diarylamine, piperidine, morpholine, thiomorpholine, pyridine, pyrazole, azepine, hydroazepine, imidazole, pyrrolidine, isoquinoline or thienopyridine, then W²and R² together are not any group selected, independently, from substituted or unsubstituted phenyl, alkyl, cycloalkyl, pyrimidine, and a triazine group.

WO 2017/140778

PCT/EP2017/053498 [00149] In one specific embodiment, the compound of formula (I), (II), (III), (IV), (V) or (VI) may not be a compound selected from the group consisting of:

[00150] In one embodiment, the compound of formula (I) has a molecular weight of from 200 to 2000 Da. Preferably the compound of formula (I) has a molecular weight of from 300 to 1000 Da. More preferably, the compound of formula (I) has a molecular weight of from 350 to 500 Da.

[00151] The compounds of the present invention may provide one or more benefits over prior art sulfonyl ureas selected from: improved microsomal stability; improved permeability; reduced Pgp liability; reduced plasma protein binding; increased half-life; improved oral bioavailability; improved AUC; improved Cmax; reduced Cyp inhibition; and improved solubility.

[00152] In one embodiment, the compounds of formula (I) offer improved pharmacokinetic characteristics. CRID3, a known sulfonylurea, has a half-life of 3.2 hours (mouse) which may lead to substantial trough levels from QD or BD dosing when the t1 /2 is extrapolated to man. The compounds of formula (I) may differ in, for example, their protein binding, metabolism and oral availability.

[00153] In one embodiment, the compounds of formula (I) have a tPSA of less than 90 A².

[00154] In one further embodiment, the compounds of formula (I) have a tPSA of less than 90 A² and a molecular weight of less than 405.

WO 2017/140778

PCT/EP2017/053498 [00155] In some embodiments of the present invention, therapeutically inactive prodrugs are provided. Prodrugs are compounds which, when administered to a mammal, are converted in whole or in part to a compound of the invention. In most embodiments, the prodrugs are pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules to exert a therapeutic effect. Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, or stability of the compound or to otherwise alter the properties of the compound. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include, but are not limited to, compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, and/or dephosphorylated to produce the active compound.

[00156] In certain embodiments, the compounds of formula (I) may exhibit improved properties compared to known anti-diabetes drugs. Such compounds of formula (I) may be viewed as very potent versions of current sulfonylurea anti-diabetes drugs. Known diabetes drugs do not target NLRP3 to any therapeutically significant extent and so it would be necessary to use very high doses to have any significant effect on the NLRP3 inflammasome. The compounds of formula (I), show advantageously improved properties in a significant decrease in IC50 versus the NLRP3 inflammasome and additionally have the benefits, not realised by existing diabetes drugs, associated with NLRP3 inhibition such as improved wound healing and other advantages described herein.

[00157] In one embodiment, the compound of formula (I) displaying these improved properties is selected from the group consisting of:

WO 2017/140778

PCT/EP2017/053498

[00158] Ina further embodiment, one or more of the compounds of formula (I) may be useful as photoswitchable compounds which may applied in a range of uses including but not limited to insulin release.

[00159] In certain embodiments of the invention one or more compounds of formula (I) may be appropriate for use as probes, such as photoaffinity probes, or as reactive intermediates which can be modified either directly or by means of a linking moiety to give biotinylated, fluorescent or photoaffinity probes. It will be appreciated that the compounds of formula (I) may be modified or derivatised by means well understood in the art to allow linkage to a molecule such as biotin, or a fluorescent group or photoaffinity label.

[00160] A number of prodrug ligands are known. In general, alkylation, acylation, or other lipophilic modification of one or more heteroatoms of the

WO 2017/140778

PCT/EP2017/053498 compound, such as a free amine or carboxylic acid residue, may reduce polarity and allow for the compound’s passage into cells. Examples of substituent groups that can replace one or more hydrogen atoms on a free amine and/or carboxylic acid moiety include, but are not limited to, the following: aryl; steroids; carbohydrates (including sugars); 1,2-diacylglycerol; alcohols; acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester (including alkyl or arylalkyl sulfonyl, such as methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as provided in the definition of an aryl given herein); optionally substituted arylsulfonyl; lipids (including phospholipids); phosphatidylcholine; phosphocholine; amino acid residues or derivatives; amino acid acyl residues or derivatives; peptides; cholesterols; or other pharmaceutically acceptable leaving groups which, when administered in vivo, provide the free amine. Any of these moieties can be used in combination with the disclosed active agents to achieve a desired effect.

[00161 ] In some embodiments, compounds with one or more chiral centers are provided. While racemic mixtures of compounds of the invention may be active, selective, and bioavailable, isolated isomers may be of interest as well. [00162] The compounds disclosed herein as active agents may contain chiral centers, which may be either of the (R) or (S) configuration, or which may comprise a mixture thereof. Accordingly, the present invention also includes stereoisomers of the compounds described herein, where applicable, either individually or admixed in any proportions. Stereoisomers may include, but are not limited to, enantiomers, diastereomers, racemic mixtures, and combinations thereof. Such stereoisomers can be prepared and separated using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds and prodrugs of the present invention. Isomers may include geometric isomers. Examples of geometric isomers include, but are not limited to, cis isomers or trans isomers across a double bond. Other isomers are contemplated among the compounds of the present invention. The isomers

WO 2017/140778

PCT/EP2017/053498 may be used either in pure form or in admixture with other isomers of the compounds described herein.

[00163] Various methods are known in the art for preparing optically active forms and determining activity. Such methods include standard tests described herein and other similar tests which are well known in the art. Examples of methods that can be used to obtain optical isomers of the compounds according to the present invention include the following:

i) physical separation of crystals whereby macroscopic crystals of the individual enantiomers are manually separated. This technique may particularly be used when crystals of the separate enantiomers exist (i.e., the material is a conglomerate), and the crystals are visually distinct;

ii) simultaneous crystallization whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;

iii) enzymatic resolutions whereby partial or complete separation of a racemate is achieved by virtue of differing rates of reaction for the enantiomers with an enzyme;

iv) enzymatic asymmetric synthesis, a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;

v) chemical asymmetric synthesis whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries;

vi) diastereomer separations whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the

WO 2017/140778

PCT/EP2017/053498 desired enantiomer;

vii) first- and second-order asymmetric transformations whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomers;

viii) kinetic resolutions comprising partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;

x) chiral liquid chromatography whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase. The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;

xi) chiral gas chromatography whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;

xii) extraction with chiral solvents whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent; and xiii) transport across chiral membranes whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two

WO 2017/140778

PCT/EP2017/053498 miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane which allows only one enantiomer of the racemate to pass through.

[00164] The compound optionally may be provided in a composition that is enantiomerically enriched, such as a mixture of enantiomers in which one enantiomer is present in excess, in particular, to the extent of 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, including 100%.

[00165] The terms (R), (S), (R,R), (S,S), (R,S) and (S,R) as used herein mean that the composition contains a greater proportion of the named isomer of the compound in relation to other isomers. In a preferred embodiment, these terms indicate that the composition contains at least 90% by weight of the named isomer and 10% by weight or less of the one or more other isomers; or more preferably about 95% by weight of the named isomer and 5% or less of the one or more other isomers. In some embodiments, the composition may contain at least 99% by weight of the named isomer and 1 % or less by weight of the one or more other isomers, or may contain 100% by weight of the named isomer and 0% by weight of the one of more other isomers. These percentages are based on the total amount of the compound of the present invention present in the composition.

[00166] The compounds of the present invention may be utilized per se or in the form of a pharmaceutically acceptable ester, amide, salt, solvate, prodrug, or isomer. For example, the compound may be provided as a pharmaceutically acceptable salt. If used, a salt of the drug compound should be both pharmacologically and pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such pharmacologically and pharmaceutically

WO 2017/140778

PCT/EP2017/053498 acceptable salts can be prepared by reaction of the drug with an organic or inorganic acid, using standard methods detailed in the literature.

[00167] Examples of pharmaceutically acceptable salts of the compounds useful according to the invention include acid addition salts. Salts of nonpharmaceutically acceptable acids, however, may be useful, for example, in the preparation and purification of the compounds. Suitable acid addition salts according to the present invention include organic and inorganic acids. Preferred salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, benzenesulfonic, and isethionic acids. Other useful acid addition salts include those formed with propionic acid, glycolic acid, oxalic acid, malic acid, malonic acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, and the like. Particular examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

[00168] An acid addition salt may be reconverted to the free base by treatment with a suitable base. Preparation of basic salts of acid moieties which may be present on a compound or prodrug useful according to the present invention may be prepared in a similar manner using a pharmaceutically

WO 2017/140778

PCT/EP2017/053498 acceptable base, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, triethylamine, or the like.

[00169] Esters of the active agent compounds according to the present invention may be prepared through functionalization of hydroxyl and/or carboxyl groups that may be present within the molecular structure of the compound. Amides and prodrugs may also be prepared using techniques known to those skilled in the art. For example, amides may be prepared from esters, using suitable amine reactants, or they may be prepared from an anhydride or an acid chloride by reaction with ammonia or a lower alkyl amine. Moreover, esters and amides of compounds of the invention can be made by reaction with a carbonylating agent (e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (e.g., 4-dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a suitable organic solvent (e.g., tetrahydrofuran, acetone, methanol, pyridine, Ν,Ν-dimethylformamide) at a temperature of 0 ^QC to 60 ^QC. Prodrugs are typically prepared by covalent attachment of a moiety, which results in a compound that is therapeutically inactive until modified by an individual’s metabolic system. Examples of pharmaceutically acceptable solvates include, but are not limited to, compounds according to the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.

[00170] In the case of solid compositions, it is understood that the compounds used in the methods of the invention may exist in different forms. For example, the compounds may exist in stable and metastable crystalline forms and isotropic and amorphous forms, all of which are intended to be within the scope of the present invention.

[00171] If a compound useful as an active agent according to the invention is a base, the desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as

WO 2017/140778

PCT/EP2017/053498 hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acids such as glucuronic acid and galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as benzoic acid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid or ethanesulfonic acid, or the like.

[00172] If a compound described herein as an active agent is an acid, the desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal or alkaline earth metal hydroxide or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminium and lithium.

[00173] According to a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of the first aspect disclosed herein, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

[00174] Suitably, the pharmaceutically acceptable carrier, diluent and/or excipient may be or include one or more of diluents, solvents, pH buffers, binders, fillers, emulsifiers, disintegrants, polymers, lubricants, oils, fats, waxes, coatings, viscosity-modifying agents, glidants and the like.

[00175] The salt forms of the compounds of the invention are especially useful due to their improved solubility.

[00176] In one embodiment, the pharmaceutical composition includes a cyclodextrin.

[00177] The cyclodextrin may be selected from alpha, beta or gamma

WO 2017/140778

PCT/EP2017/053498 cyclodextrins.

[00178] In one embodiment, the cyclodextrin is selected from a methyl cyclodextrin, a hydroxypropyl cyclodextrin and a sulfobutylether cyclodextrin. [00179] It has been found that cyclodextrins provide significant advantages in formulation and delivery of the compounds of the invention.

[00180] Cyclodextrin formulations such as for example, one or more compounds of the invention with hydroxypropyl beta cyclodextrin or methyl beta cyclodextrin, may have uses in cholesterol sequestration/cholesterol lowering or via NLRP3 inhibition for Non-alcoholic steatohepatitis (NASH) and also in Alzheimer’s Disease (AD).

[00181] Diluents may include one or more of microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, and the like. Binders may include one or more of povidone, starch, stearic acid, gums, hydroxypropylmethyl cellulose and the like. Disintegrants may include one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate and the like. Solvents may include one or more of ethanol, methanol, isopropanol, chloroform, acetone, methylethyl ketone, methylene chloride, water and the like. Lubricants may include one or more of magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, glyceryl behenate and the like. A glidant may be one or more of colloidal silicon dioxide, talc or corn starch and the like. Buffers may include phosphate buffers, borate buffers and carbonate buffers, although without limitation thereto. Fillers may include one or more gels inclusive of gelatin, starch and synthetic polymer gels, although without limitation thereto. Coatings may comprise one or more of film formers, solvents, plasticizers and the like. Suitable film formers may be one or more of hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, povidone, sodium carboxymethyl cellulose, polyethylene glycol, acrylates and the like. Suitable solvents may be one or more of water, ethanol, methanol, isopropanol, chloroform, acetone,

WO 2017/140778

PCT/EP2017/053498 methylethyl ketone, methylene chloride and the like. Plasticizers may be one or more of propylene glycol, castor oil, glycerin, polyethylene glycol, polysorbates, and the like.

[00182] Reference is made to the Handbook of Excipients 6^th Edition, Eds. Rowe, Sheskey & Quinn (Pharmaceutical Press), which provides non-limiting examples of excipients which may be useful according to the invention.

[00183] It will be appreciated that the choice of pharmaceutically acceptable carriers, diluents and/or excipients will, at least in part, be dependent upon the mode of administration of the formulation. By way of example only, the composition may be in the form of a tablet, capsule, caplet, powder, an inhalable liquid (e.g. solution, suspension), an injectable liquid, a suppository, a slow release formulation, an osmotic pump formulation or any other form that is effective and safe for administration.

[00184] Suitably, the pharmaceutical composition is for the treatment or prevention of a disease, disorder or condition in a mammal.

[00185] A third aspect of the invention resides in a method of treatment or prevention of a disease, disorder or condition including the step of administering an effective amount of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect, to thereby treat or prevent the disease, disorder or condition.

[00186] A fourth aspect of the invention provides for a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect, for use in the treatment or prevention of a disease, disorder or condition.

[00187] A fifth aspect of the invention provides for use of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition.

WO 2017/140778

PCT/EP2017/053498 [00188] As generally used herein, the terms “administering” or “administration”, and the like, describe the introduction of the compound or composition to a mammal such as by a particular route or vehicle. Routes of administration may include topical, parenteral and enteral which include oral, buccal, sub-lingual, nasal, anal, gastrointestinal, subcutaneous, intramuscular and intradermal routes of administration, although without limitation thereto.

[00189] By “treat”, “treatment” or “treating” is meant administration of the compound or composition to a subject to at least ameliorate, reduce or suppress existing signs or symptoms of the disease, disorder or condition experienced by the subject.

[00190] By “prevent”, “preventing” or “preventative” is meant prophylactically administering the formulation to a subject such as a mammal who does not exhibit signs or symptoms of a disease, disorder or condition, but who is expected or anticipated to likely exhibit such signs or symptoms in the absence of prevention. Preventative treatment may at least lessen or partly ameliorate expected symptoms or signs.

[00191 ] As used herein, “effective amount” refers to the administration of an amount of the relevant active agent sufficient to prevent the occurrence of symptoms of the condition being treated, or to bring about a halt in the worsening of symptoms or to treat and alleviate or at least reduce the severity of the symptoms. The effective amount will vary in a manner which would be understood by a person of skill in the art with patient age, sex, weight, etc. An appropriate dosage or dosage regime can be ascertained through routine trial.

[00192] As used herein, the terms subject or individual or patient may refer to any mammalian subject. Mammals may include, but are not restricted to, primates, livestock animals (e.g. sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. cats, dogs) and captive wild animals (e.g. foxes, deer, dingoes). A preferred subject is a human in need of treatment for a disease,

WO 2017/140778

PCT/EP2017/053498 disorder or condition as described herein. However, it will be understood that the aforementioned terms do not imply that symptoms are necessarily present. [00193] In one particular embodiment, the disease, disorder or condition is one which is responsive to inhibition of activation of the NLRP3 inflammasome. [00194] According to this embodiment, the compound of the first aspect, or pharmaceutically effective salt, solvate or prodrug thereof is a specific inhibitor of NLRP3.

[00195] In a further embodiment, the disease, disorder or condition is responsive to modulation of one or more of IL-1 β, IL-17, IL-18, IL-1 cc, IL-37, IL-33 and Th17 cells.

[00196] In one embodiment, the modulation is inhibition of one or more of IL-1 β, IL-17, IL-18, IL-1 cc, IL-37, and IL-33.

[00130] In one embodiment, the modulation of Th17 cells, is by inhibition of production and/or secretion of IL-17.

[00197] In general embodiments, the disease, disorder or condition is a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the respiratory system, the central nervous system, is a cancer or other malignancy and/or is caused by or associated with a pathogen.

[00198] It will be appreciated that these general embodiments defined according to broad categories of diseases, disorders and conditions are not mutually exclusive. In this regard any particular disease, disorder or condition may be categorized according to more than one of the above general embodiments. A non-limiting example is Type I diabetes which is an autoimmune disease and a disease of the endocrine system.

[00199] In one embodiment, the disease, disorder or condition is of the immune system. In particular embodiments, the disease, disorder or condition

WO 2017/140778

PCT/EP2017/053498 is an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition.

[00200] In one embodiment, the disease, disorder or condition is of the skin.

[00201] In one embodiment, the disease, disorder or condition is of the cardiovascular system.

[00202] In one embodiment, the disease, disorder or condition is a cancer, tumour or other malignancy. As used herein, cancers tumours and malignancies, refer to diseases disorders or conditions, or to cells or tissues associated with the diseases, disorders or conditions, characterized by aberrant or abnormal cell proliferation, differentiation and/or migration often accompanied by an aberrant or abnormal molecular phenotype that includes one or more genetic mutations or other genetic changes associated with oncogenesis, expression of tumour markers, loss of tumour suppressor expression or activity and/or aberrant or abnormal cell surface marker expression. In general embodiments, cancers, tumours and malignancies may include sarcomas, lymphomas, leukemias, solid tumours, blastomas, gliomas, carcinomas, melanomas and metastatic cancers, although without limitation thereto. A more comprehensive listing of cancers tumours and malignancies may be found at the National Cancer Institute’s website http://www.cancer.gov/cancertopics/types/alphalist.

[00203] In one embodiment, the disease, disorder or condition is of the renal system.

[00204] In one embodiment, the disease, disorder or condition is of the gastro-intestinal tract.

[00205] In one embodiment, the disease, disorder or condition is of the respiratory system.

[00206] In a further embodiment, the disease, disorder or condition is of the endocrine system.

WO 2017/140778

PCT/EP2017/053498 [00207] In one embodiment, the disease, disorder or condition is of the central nervous system (CNS).

[00208] In one embodiment, the disease, disorder or condition is caused by, or is associated with, a pathogen. The pathogen may be a virus, a bacterium, a protist, a worm or a fungus or any other organism capable of infecting a mammal, although without limitation thereto.

[00209] Non-limiting examples of viruses include influenza virus, cytomegalovirus, Epstein Barr Virus, human immunodeficiency virus (HIV), alphavirus such as Chikungunya and Ross River virus, flaviviruses such as Dengue virus, Zika virus and papillomavirus, although without limitation thereto. [00210] Non-limiting examples of pathogenic bacteria include Staphylococcus aureus, Helicobacter pylori, Bacillus anthracis, Bordatella pertussis, Corynebacterium diptheriae, Clostridium tetani, Clostridium botulinum, Streptococcus pneumoniae, Streptococcus pyogenes, Listeria monocytogenes, Hemophilus influenzae, Pasteurella multicida, Shigella dysenteriae, Mycobacterium tuberculosis, Mycobacterium leprae, Mycoplasma pneumoniae, Mycoplasma hominis, Neisseria meningitidis, Neisseria gonorrhoeae, Rickettsia rickettsii, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Propionibacterium acnes, Treponema pallidum, Chlamydia trachomatis, Vibrio cholerae, Salmonella typhimurium, Salmonella typhi, Borrelia burgdorferi and Yersinia pestis, although without limitation thereto.

[00211] Non-limiting examples of protists include Plasmodium, Babesia, Giardia, Entamoeba, Leishmania and Trypanosomes, although without limitation thereto.

[00212] Non-limiting examples of worms include helminths inclusive of schistisimes, roundworms, tapeworms and flukes, although without limitation thereto.

WO 2017/140778

PCT/EP2017/053498 [00213] Non-limiting examples of fungi include Candida and Aspergillus species, although without limitation thereto.

[00214] Further relevant diseases, disorders or conditions may be selected from the group consisting of those recited in the journal article Menu et al., Clinical and Experimental Immunology, 166, 1-15, 2011, found at: http://onlinelibrary.wiley.eom/store/10.1111 /j.13652249.2011,04440.x/asset/j.13652249.2011.04440.x.pdf?v=1 &t=i60c1 phf&s=d26f50a2622926cc6b4bc855bd911 ae9dc9750cf.

[00215] In particular embodiments, the disease, disorder or condition is selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID) and sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren’s syndrome and Schnitzler syndrome; macrophage activation syndrome; Blau syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), asthma such as allergic asthma and steroidresistant asthma, asbestosis, silicosis and cystic fibrosis; dermatitis including contact dermatitis; central nervous system diseases including Parkinson’s

WO 2017/140778

PCT/EP2017/053498 disease, Alzheimer’s disease, motor neuron disease, Huntington’s disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudogout; ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD), uveitis, corneal infection and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy, nephrocalcinosis and diabetic nephropathy; liver disease including nonalcoholic steatohepatitis (NASH) and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, relapsing polychondritis; viral infections including alpha virus (Chikungunya, Ross River) and flavivirus (Dengue, Zika), flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia; polymyositis; stroke including ischemic stroke; myocardial infarction including recurrent myocardial infarction; congestive heart failure; embolism; cardiovascular disease; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; ischaemia reperfusion injury and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

[00216] In one embodiment, the disease, disorder or condition is an autoinflammatory disease such as cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), Neonatal onset multisystem inflammatory disease (NOMID), Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor antagonist (DIRA), Majeed syndrome, or pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA).

WO 2017/140778

PCT/EP2017/053498 [00217] In another embodiment, the disease, disorder or condition is

Parkinson’s disease or Huntington’s disease.

[00218] In another embodiment, the disease, disorder or condition is gout or juvenile idiopathic arthritis.

[00219] In another embodiment, the disease, disorder or condition is nonalcoholic steatohepatitis (NASH).

[00220] In another embodiment, the disease, disorder or condition is oxalate nephropathy or nephrocalcinosis.

[00221 ] In another embodiment, the disease, disorder or condition is uveitis.

[00222] In another embodiment, the disease, disorder or condition is hidradenitis suppurativa (HS).

[00223] In another embodiment, the disease, disorder or condition is myelodisplastic syndrome, macrophage activation syndrome, Schnitzler syndrome, adult-onset Still’s disease, or Behget’s Disease.

[00224] In one non-limiting example of those described, the disease, disorder or condition being treated is NASH. NLRP3 inflammasome activation is central to inflammatory recruitment in NASH, and inhibition of NLRP3 may both prevent and reverse liver fibrosis. Compounds of the present invention, by interrupting the function of NLRP3 inflammasomes in liver tissue, can cause histological reductions in liver inflammation, decreased recruitment of macrophages and neutrophils, and suppression of NF-κΒ activation. Inhibition of the NLRP3 can reduce hepatic expression of pro-IL-1 β and normalized hepatic and circulating IL-1 β, IL-6 and MCP-1 levels thereby assisting in treatment of the disease.

[00225] In a further non-limiting example of those described, the disease, disorder or condition being treated is severe steroid resistant (SSR) asthma. Respiratory infections induce an NLRP3 inflammasome/caspase-1/IL-1 β signaling axis in the lungs that promotes SSR asthma. The NLRP3 inflammasome recruits, and activates, pro-caspase-1 to induce IL-1 β

WO 2017/140778

PCT/EP2017/053498 responses. NLRP3 inflammasome-induced IL-1 β responses are therefore important in the control of infections, however, excessive activation results in aberrant inflammation and has been associated with the pathogenesis of SSR asthma and COPD. The administration of compounds of the first aspect that target specific disease processes, are more therapeutically attractive than nonspecifically inhibiting inflammatory responses with steroids or IL-1 β. Targeting the NLRP3 inflammasome/caspase-1/IL-1 β signaling axis with the compounds of the first aspect may therefore be useful in the treatment of SSR asthma and other steroid-resistant inflammatory conditions.

[00226] In one further non-limiting example of those described, the disease, disorder or condition being treated is Parkinson’s disease. Parkinson’s is the most common neurodegenerative movement disorder and is characterized by a selective loss of dopaminergic neurons, accompanied by the accumulation of mis-folded α-synuclein (Syn) into Lewy bodies that are pathological hallmarks of the disease. Chronic microglial neuroinflammation is evident early in the disease, and has been proposed to drive pathology.

[00227] A central role for microglial NLRP3 is postulated in Parkinson’s progression. The NLRP3 inflammasome is activated by fibrillar Syn via a Syk kinase dependent mechanism, and also occurs in the absence of Syn pathology at the early stages of dopaminergic degeneration, and drives neuronal loss. The compounds of the first aspect may block NLRP3 inflammasome activation by fibrillar Syn or mitochondrial dysfunction and thereby confer effective neuroprotection of the nigrostriatal dopaminergic system and assist with treatment of Parkinson’s.

[00228] In a sixth aspect of the invention there is provided a method of diagnosing a disease, disorder or condition in a mammal including the step of administering a labelled compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, to the mammal or to a biological sample obtained from the mammal to facilitate diagnosis of the disease, disorder or condition in the mammal.

WO 2017/140778

PCT/EP2017/053498 [00229] Inflammasome activation, in particular that of the NLRP3 inflammasome, is known to drive initiation, progression and chronic development of a vast number of inflammatory diseases. The sulfonylureas and related compounds of the first aspect are potent and specific direct inhibitors of NLRP3. Accordingly, a chemical probe specific for NLRP3, which is present in immune cells during inflammation has potential utility in diagnosing inflammatory and other related diseases. An NRLP3 activation probe comprising a compound of the first aspect could act as an effective surrogate biomarker of inflammatory disease for ex vivo (blood) or in vivo (MRI, PET etc.) diagnostics. A compound of the first aspect (or a pharmaceutically effective salt, solvate or prodrug thereof) could also be used in other ex-vivo and/or in in-vitro diagnostic methods.

[00230] The use of the compounds of formula (I) in diagnosing inflammatory and other related diseases may be achieved by near infrared fluorescent imaging and ex vivo characterisation of immune cells by degree of inhibition of IL-1 beta, pro-caspase 1 cleavage and IL-18 levels. In particular, peripheral blood monocytes (PMBCs), macrophages, dendritic cells, CD4⁺ T cells, Th17 cells, Th1 cells and Th2 cells are relevant. In vivo diagnostics may use magnetic resonance imaging (MRI), employing ²H (deuterium), ¹³C, ¹⁹F and/or ¹⁵N labelled variants of compounds of the present invention given to a patient IV, IM, SC, PO, topical, IT, etc.

[00231] In vivo diagnostics using positron emission tomography (PET) are also appropriate. PET is a molecular imaging technique that requires specific probes radiolabelled with short-lived positron emitting radionuclides. Typical isotopes include ¹¹C, ¹³N, ¹⁵0,¹⁸F, ⁶⁴Cu, ⁶²Cu, ¹²⁴l, ⁷⁶Br, ⁸²Rb and ⁶⁸Ga, with ¹⁸F being the most clinically utilized. In particular it is possible to produce in a simple manner a stable ⁶⁴Cu or ⁶²Cu salt of one or more of the compounds of formula (I) by simple ion exchange with a sodium (or other monovalent cation) salt of said compounds. This enables rapid preparation of a diagnostic probe for radioimaging, PET and the like whereby the intensity, location and temporal

WO 2017/140778

PCT/EP2017/053498 accretion of the diagnostic probe is able to identify the degree and/or the location of immune cells with activated NLRP3 as a surrogate biomarker of the patients inflammatory state, and site of inflammation within the body. They will also be useful for application to biological samples removed from the body i.e.

in vitro diagnosis.

[00232] FIG 1 evidences complex formation between the sodium form of MCC950 (CRID3), a sulfonylurea, and copper chloride by using isothermal titration calorimetry (ITC). The results show that copper (II) ions form a strong complex with MCC950, comparable to the complex with EDTAx2Na and much stronger than with EDTA free acid. Formation of MCC950:Cu(ll) complex was endothermic with enthalpy being positive which suggests that the process was entropy driven with the presence of strong hydrophobic interactions. This is a strong indication that compounds of formula (I), bearing the same core functional sulfonyl and urea moieties, will achieve the same degree of complexation thereby proving for their use in diagnostics, as described above.

[00233] A seventh aspect of the invention resides in a method of modulating the activity of a biological target comprising the step of exposing the biological target to a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof. The method may be an ex-vivo or an in-vitro method.

[00234] The biological target may be selected from the group consisting of NLRP3 inflammasome, IL-1 β, IL-17, IL-18, IL-1 oc, IL-37, IL-33 and Th17 cells. Preferably the target is NLRP3 inflammasome.

[00235] The modulation may be as described previously for the third to fifth aspects.

[00236] As generally used herein, a biological sample may include cells, tissues, fluids, molecules or other biological materials obtained, or obtainable, from a mammal. Non-limiting examples include urine, blood and fractions thereof such as serum, plasma, lymphocytes and erythrocytes, cerebrospinal

WO 2017/140778

PCT/EP2017/053498 fluid, PAP smears, nasal and ocular secretions, amniotic fluid, faeces, semen, tissue and/or organ biopsies and nucleic acid (e.g. DNA, RNA) or protein samples, although without limitation thereto.

[00237] The following experimental section describes in more detail the characterisation of certain of the compounds of the invention and their efficacy. The intention is to illustrate certain specific embodiments of the compounds of the invention and their efficacy without limiting the invention in any way.

EXPERIMENTAL

General Methods

r²-nh₂	A	0 r¹-s-nh₂ - O
		r²-nco _k, ,,
		- NaH, THF
r²-co₂h --		C

(9

O W R'-S-NH ^H

II o

Method A:

A1: To a solution of R² amine intermediate (1 eq.) with or without base such as, but not exclusively, triethylamine (1.2 eq.) in an anhydrous aprotic solvent such as, but not exclusively, tetrahydrofuran or dichloromethane was added triphosgene (0.4 to 1.1 eq.). The reaction was stirred at ambient temperature or, where necessary, heated at reflux until completion, typically from 2 to 18 h.

A2: To di-t-butyldicarbonate (1.2-1.4 eq.) in anhydrous acetonitrile or THF was added DMAP (15-100 mol%), after 5 minutes, a solution of R² amine intermediate (1.0 eq.) in acetonitrile was added. The reaction mixture was stirred for 30-60 min at room temperature.

Method B:

B1: The R² carboxylic acid intermediate (1 eq.) was dissolved in an aprotic

WO 2017/140778

PCT/EP2017/053498 solvent such as toluene with or without 2 drops of DMF and a chlorinating agent such as thionyl chloride (2 eq.) added. The reaction mixture was heated at reflux until completion, then concentrated in vacuoto give the corresponding R² acid chloride intermediate.

Alternative methods or forming the acid chloride are also equally useful here for example the above procedure can be carried out without toluene and DMF thereby using thionyl chloride as both solvent and chlorinating agent.

The R² acid chloride intermediate was dissolved in acetone and added dropwise to a solution of sodium azide (1.5 eq) in a water:acetone (50:50) solution at 0 °C. Iced water was added to precipitate the resulting R² acylazide intermediate which was dissolved in toluene and dried (MgSO4) prior to adding the solution in a drop-wise fashion to anhydrous toluene at reflux while maintaining a constant flow of inert gas. The reaction was heated until completion, typically 2 h, to give the R² isocyanate.

B2: The R² acid chloride (formed as indicated in method B1) in dry CH₂CI₂ was added NaN₃ (2.0 eq.) at 0 °C. The reaction mixture was stirred at room temperature for 1 h and extracted into EtOAc. The organic layer was washed with H₂O (15 mL), dried (MgSO4), and carefully evaporated to give acyl azide. The acyl azide was dissolved in dry toluene and heated to 100 °C for 2 h. The solvent was removed to give crude R² isocyanate.

Method C:

C1: R¹ sulfonamide intermediate (1 eq.) was dissolved in anhydrous THF and treated with NaH (1 eq.) under reduced pressure. The mixture was heated to reflux for 2 h then cooled to room temperature and R² isocyanate intermediate in THF added under nitrogen atmosphere. The reaction mixture was stirred at reflux until completion.

C2: R¹ sulfonamide intermediate (1 eq.) was dissolved in anhydrous THF or anhydrous methanol and treated with NaH (1 eq.) under reduced pressure.

Once effervescence ceased the R² isocyanate intermediate was added and the

WO 2017/140778

PCT/EP2017/053498 reaction mixture was stirred at ambient temperature overnight.

C3: To R¹ sulfonamide intermediate (1 eq) in anhydrous THF (5 mL/mmol) was added NaH (1 eq) at 0 °C and stirred for 30 min to 2 h, or until completion, at ambient temperature under nitrogen atmosphere. Again cooled to 0 °C, R²isocyanate (1.0 eq) in THF was added and stirred at ambient temperature until completion, typically 2 to 16 h.

C4: To crude R² isocyanate (1.0 eq) in anhydrous THF or DCM (5-11 mL/mmol) was added R¹ sulfonamide (1.0 eq) followed by base such as triethylamine, DIPEA, or DBU (1-2 eq) and the reaction mixture stirred at ambient temperature overnight.

C5: To R¹ sulfonamide intermediate (1 eq) in anhydrous MeOH (5 mL/mmol) was added NaOMe (1 eq) [alternatively: a 1.0 mM solution of freshly prepared sodium methoxide (1 eq) was added to a 1.0 mM solution of R¹ sulfonamide (1 eq) in anhydrous methanol]. The solvent was then removed in vacuo. The salt was suspended in anhydrous aprotic solvent such as acetonitrile or THF, the R²isocyanate (1.0 eq) in anhydrous aprotic solvent such as acetonitrile or THF was added and the mixture stirred at ambient temperature overnight. The solution was then heated at reflux until completion, typically 90 min.

C6: R¹ sulfonamide (1.0 eq.) was dissolved in anhydrous THF under a nitrogen atmosphere. Solid sodium methoxide (1.0 eq mmol) was added in one portion. This mixture was stirred at ambient temperature for 3 h. A solution of the R²isocyanate (1.17 eq) in THF was added drop wise. The reaction mixture was stirred at room temperature overnight.

R-NH₂

O

II

R-S-CI II O

O r-s-nh₂

II

O

WO 2017/140778

PCT/EP2017/053498

Method D:

A solution of amine (1.0 eq) in acetonitrile (7-12 mL/mmol) at 0 °C was treated with c.HCI (1.25-2.25 mL/mmol) in H₂O (0.5-1.2 mL/mmol) followed by aqueous solution of NaNO₂ (1.2 eq) dissolved in H₂O (0.3-0.5 mL/mmol of NaNO₂). The resulting solution was stirred at 0 °C for 45 min. AcOH (0.5-1.2 mL/mmol), CuCI₂.2H₂O (0.5 eq) and CuCI (0.05 eq) were sequentially added to the above mixture and purged with SO₂ gas for 20 min at 0 °C. The resulting reaction mixture was stirred at 0°C- 10°C until completion.

Method E:

E1: A solution of sulfonyl chloride (1 eq) in THF (10-20 mL/mmol) was cooled to -78 °C and ammonia gas was bubbled through the solution for 15 min, stirring was continued for a further 30 min then allowed to warm to ambient temperature and stirred for 2h or until completion.

E2: A solution of sulfonyl chloride (1 eq) in acetone (20 mL/mmol) was treated with a solution of NH₄HCO₃ (4 eq) dissolved in water (1.5 mL/mmol of NH4HCO3) at ambient temperature and stirred for 4 h or until completion.

Method F

General Procedure for the synthesis of triazoles

Alkyne (1 eq) and azide (1.2 eq), 5 mol% CuSO₄, 10 mol% NaAsc solution in DMSO (500 pL) were stirred at room temperature until completion, typically 12 h.

WO 2017/140778

PCT/EP2017/053498

Synthesis of R¹ sulfonamide intermediates:

Morpholine-4-sulfonamide

Morpholine (1.98 mL, 22.9 mmol) was added slowly to a mixture of sulfuryl chloride (5.5 mL, 68.8 mmol) in acetonitrile (15 mL) at ambient temperature. The resulting reaction mixture was heated to reflux for 24 h. The solvent was removed in vacuo and the residue azeotroped twice with toluene to give morpholine-4-sulfonyl chloride as a light yellow oil (2.8 g, 67%). The crude product was used directly in the next step without further purification. ¹H NMR (400 MHz, DMSO-de): δ 3.79 (t, J = 4.0 Hz, 4H), 3.28 (t, J = 4.0 Hz, 4H).

Morpholine-4-sulfonyl chloride (0.5 g, 4.3 mmol) in acetone (0.5 mL) was added to aq NH₃ (1.5 mL, NH₄OH in H₂O, 28% NH₃ basis) at 0 °C and stirred at same temperature for 2 h. The solvent was removed in vacuo and the residue azeotroped twice with toluene. The residue was purified by column chromatography on silica gel using 2% MeOH-DCM eluent to give morpholine4-sulfonamide as white solid (270 mg, 60%). ¹H NMR (400 MHz, DMSO-d₆): δ 6.82 (bs, 2H), 3.65 (t, J = 4.0 Hz, 4H), 2.92 (t, J = 4.0 Hz, 4H).

4-methylpiperazine-1 -sulfonamide

o=s=o

I Cl o=s=o nh₂

-Methylpiperazine (2.0 g, 19.9 mmol) was added slowly to a mixture of sulfuryl chloride (4.83 mL, 59.9 mmol) in acetonitrile (15 mL) at room temperature, the resulting reaction mixture was heated to reflux for 24 h. The solvent was

WO 2017/140778

PCT/EP2017/053498 removed in vacuo and the residue azeotroped twice with toluene to give 4methylpiperazine-1 -sulfonyl chloride hydrochloride salt as a brown solid (2.1 g, crude). The crude product was used directly in the next step without purification.

¹H NMR (400 MHz, DMSO-d₆): δ = 3.95 (bs, 2H), 3.60 (bs, 4H), 3.39-3.34 (m,

2H), 2.81 (3H, s).

To a solution of 4-methylpiperazine-1 -sulfonyl chloride hydrochloride in acetone (5.0 mL) was added aq NH₃ (5.0 mL, NH₄OH in H₂O, 28% NH₃ basis) at 0 °C, the resulting reaction mixture was stirred at room temperature for about 2 h. The solvent was removed in vacuo and the residue azeotroped twice with toluene. The residue was purified by reverse phase column chromatography using acetonitrile/water as mobile phase to afford 4-methylpiperazine-1sulfonamide as an off white solid (125 mg, 21%). ¹H NMR (400 MHz, DMSOd₆): δ = 6.71 (bs, 2H), 2.91 (t, J= 4.0 Hz, 4H), 2.34 (t, J= 4.0 Hz, 4H), 2.15 (s, 3H).

-isopropyl-1 H-pyrazole-3-sulfonamide

NH

1-lsopropyl-1 /7-pyrazol-3-amine was reacted to 1-isopropyl-1/7-pyrazole-3sulfonyl chloride, a brown liquid, using general method D (0.5 g, 43 %). ¹H NMR (400 MHz, CDCI3): δ = 7.55 (s, 1H), 6.88 (s, 1H), 4.66-4.63 (m, 1H), 3.6 (br.s., 2H), 1.59 (d, J= 6.8 Hz, 6H). LCMS (m/z): 209.0 (M+1)⁺. The sulfonyl chloride was converted using general method E1 to give the titled compound as yellow solid (0.45 g, 82%). ¹H NMR (300 MHz, DMSO-d6): δ = 7.9 (d, J= 2.4 Hz, 1H), 7.36 (s, 2H), 6.55 (d, J = 2.1 Hz, 1H), 4.57-4.53 (m, 1H), 1.42 (d, J = 6.9 Hz, 6H). LCMS (m/z): 190.0 (M+1)⁺.

WO 2017/140778

PCT/EP2017/053498

100

Other R¹ sulphonamide intermediates are commercially available and/or may be prepared by routine synthetic methods. WO 2016/131098 for example (see pages 90-130) discloses the synthesis of the following R¹ sulphonamide intermediates which may be used in the synthesis of compounds of the present invention:

Cyclohexanesulfonamide

Cyclopentanesulfonamide

5-((dimethylamino)methyl)furan-2-sulfonamide

Furan-2-sulfonamide

5-methylfuran-2-sulfonamide

5-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2sulfonamide

4-(prop-1-en-2-yl)furan-2-sulfonamide d₆-4-(prop-1-en-2-yl)furan-2-sulfonamide

4-(prop-1-en-2-yl)furan-2-sulfonamide

4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide d₆-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide

-benzyl-1 /7-1,2,4-triazole-3-sulfonamide

-methyl-1 /7-pyrazole-3-sulfonamide

- (trifl uo ro methyl)-1 H-pyrazole-3-sulfonamide

-isopropyl-1 /7-pyrazole-4-sulfonamide

-cyclopropyl-1 H-pyrazole-3-sulfonamide

- (ieri-butyl)-1 /7-pyrazole-3-sulfonamide

-cyclohexyl-1 H-pyrazole-3-sulfonamide

-phenyl-1 H-pyrazole-3-sulfonamide

WO 2017/140778

PCT/EP2017/053498

101

1-benzyl-1 /7-pyrazole-3-sulfonyl chloride

-(1 -phenylethyl)-1 H-pyrazole-3-sulfonamide

- (2-(pi peridi n-1 -yl)ethyl)-1 /7-pyrazole-3-sulfonamide

1,5-dimethyl-1 /7-pyrazole-3-sulfonamide

-methyl-5-(trifluoromethyl)-1 /7-pyrazole-3-sulfonamide

-isopropyl-5-(trifl uo ro methyl)-1 /7-pyrazole-3-sulfonamide

5-isopropyl-1 -methyl-1 /7-pyrazole-3-sulfonamide

5-(2-hydroxypropan-2-yl)-1 -methyl-1 H-pyrazole-3-sulfonamide

-benzyl-5-(2-hydroxypropan-2-yl)-1 /7-pyrazole-3-sulfonamide

5-(2-hydroxypropan-2-yl)-1 -phenyl-1 /7-pyrazole-3-sulfonamide

5-(dimethylamino)naphthalene-1 -sulfonamide

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3dihydrobenzo[b]thiophene-6-sulfonamide 1,1 -dioxide

3-azidobenzenesulfonamide

A/-(3-Sulfamoylphenyl)pent-4-ynamide

Benzene-1,3-disulfonamide

A/¹,/\/¹-dimethylbenzene-1,3-disulfonamide

Methyl 3-sulfamoylbenzoate

3-(4-phenyl-1 H-1,2,3-triazol-1 -yl)benzenesulfonamide

A/-(prop-2-yn-1-yl)-3-(4-sulfamoylphenyl)propanamide benzo[d][1,3]dioxole-5-sulfonamide

Pyridine-4-sulfonamide

Pyridine-3-sulfonamide

Pyridine-2-sulfonamide

WO 2017/140778

PCT/EP2017/053498

102

4-(trifluoromethyl)pyridine-2-sulfonamide

3- (3-(trifluoromethyl)-3/7-diazirin-3-yl)benzenesulfonamide

2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)-N-(4sulfamoylphenethyl)acetamide

4- (2-(7-Nitrobenzo[c][1,2,5]oxadiazol-4- ylamino)ethyl)benzenesulfonamide

2-(7-(Dimethylamino)-2-oxo-2/7-chromen-4-yl)-A/-(4- sulfamoylphenethyl)acetamide

Synthesis of R¹ and R² amine intermediates:

9H-carbazol-9-amine

9H-carbazole (2.0 g, 12 mmol) was dissolved in acetonitrile (80 mL) and acetic acid (20 mL) then cooled to 0 °C and c.HCLwater (4:2, 6 mL) added. The solution was treated with a solution of sodium nitrite (1 g, 14.4 mmol) in water (4 mL) drop-wise over 10 mins. The reaction was stirred at 0-10 °C for 3 hours or until completion then diluted with water and extracted using ethyl acetate. The organics were washed with water, brine then dried (Na₂SO₄) and concentrated in vacuo to give 9-nitro-9H-carbazole as a yellow solid used directly in the next reaction step.

Zinc (9.7 g, 150 mmol) and ammonium chloride (8 g, 150 mmol) in THF (50 mL) and water (15 mL) was cooled to 0 °C and 9-nitro-9H-carbazole in THF (5 mL) was added dropwise and stirring continued for 2h or until completion. The reaction was diluted using ethyl acetate and filtered through celite then the organic phase was washed using water, brine, dried (Na₂SO₄) and

WO 2017/140778

PCT/EP2017/053498

103 concentrated in vacuo. The crude product was purified by column chromatography on silica using 5% ethyl acetate:hexanes eluent to give the titled compound as a semi-solid (3.3 g, 42%).¹H NMR (400 MHz, DMSO-ofe) δ =

8.10 (d, J=7.7 Hz, 1H), 7.59 (d, J=7.7 Hz, 1H), 7.45 (t, J=7.7 Hz, 1H), 7.17 (t, J =7.7 Hz, 1H), 5.83 (s, 1H).

Other R¹ and R² amine intermediates are commercially available and/or may be prepared by routine synthetic methods. WO 2016/131098 for example (see pages 130-157) discloses the synthesis of the following R¹ and R² amine intermediates which may be used in the synthesis of compounds of the present invention:

1-methyl-1 /7-pyrazol-3-amine HCI

- (trifl uoro methyl)-1 H-pyrazol-3-amine

-isopropyl-1 H-pyrazol-3-amine

-cyclopropyl-1 H-pyrazol-3-amine

- (tert-butyl)-1 /7-pyrazol-3-amine

-cyclohexyl-1 H-pyrazol-3-amine

-phenyl-1 /7-pyrazol-3-amine

1-benzyl-1 /7-pyrazol-3-amine

-(1 -phenylethyl)-1 H-pyrazol-3-amine

- (2-(pi peridi n-1 -yl)ethyl)-1 /7-pyrazol-3-amine

1,5-dimethyl-1 /7-pyrazol-3-amine

-methyl-5-(trifluoromethyl)-1 /7-pyrazol-3-amine

-methyl-5-(prop-1 -en-2-yl)-1 /7-pyrazol-3-amine

Ethyl 1-benzyl-3-nitro-1 /7-pyrazole-5-carboxylate

WO 2017/140778

PCT/EP2017/053498

104

Ethyl 1-benzyl-3-nitro-1 /7-pyrazole-5-carboxylate

3- (2,5-dimethyl-1 H-py rrol-1 -yl)-1 -phenyl-1 /7-pyrazole

8-bromo-1,2,3,5,6,7-hexahydro-s-indacen-4-amine

8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-amine

8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine

3.5.6.7- tetrahydro-2/7-indeno[5,6-d]furan-8-amine

4- bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine

3.5.6.7- tetrahydro-2H-indeno[5,6-b]furan-4-amine benzo[1,2-b:4,5-b']difuran-4-amine

3-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline

Synthesis of R² acid intermediates:

R² acid intermediates are commercially available and/or may be prepared by routine synthetic methods. WO 2016/131098 for example (see pages 166-169) discloses the synthesis of the following R² acid intermediates which may be used in the synthesis of compounds of the present invention:

2.3.6.7- tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carboxylic acid

Benzo[c/|[1,3]dioxole-4-carboxylic acid

WO 2017/140778

PCT/EP2017/053498

105

Compounds

Example 1: N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl) morpholine-4-sulfonamide

4-lsocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and morpholine-4-sulfonamide were used in general method C2 to give the titled compound as a white solid (25 mg, 24%). ¹H NMR (400 MHz, DMSO-d6): δ = 7.98 (bs, 1H), 6.94 (s, 1H), 3.63 (t, J= 4.0 Hz, 4H), 3.18 (t, J= 4.0 Hz, 4H), 2.81 (t, J= 8.0 Hz, 4H), 2.68 (t, J= 8.0 Hz, 4H), 2.02-1.95 (m, 4H); LCMS Purity: >95%; LCMS (m/z): 366 [M+H]⁺.

Example 2: /7-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4methylpiperazine-1 -sulfonamide

4-lsocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4-Methylpiperazine-1-sulfonamide were used in general method C3 to give the titled compound as a white solid (60 mg, 55%).¹H NMR (600 MHz, DMSO-de): δ = 7.96 (bs, 1H), 6.94 (s, 1H), 3.20 (t, J = 6.0 Hz, 4H), 2.80 (t, J= 6.0 Hz, 4H), 2.69 (t, J= 6.0 Hz, 4H), 2.37 (t, J= 6.0 Hz, 4H), 2.19 (s, 3H), 2.00-1.95 (m, 4H). ¹³C NMR (150 MHz, DMSO-d₆): δ = 150.6, 143.5,

137.4, 129.6, 118.1, 54.3, 46.5, 45.9, 32.9, 30.7, 25.5. LCMS Purity: >95%; LCMS (m/z): 379 [M+H] ⁺. HRMS calculated for C18H27N4O3S1 (M+H)⁺379.1798, found 379.1795.

WO 2017/140778

PCT/EP2017/053498

106

Example 3: Λ/-[1 ^^^^J-hexahydro-s-indacen^-yll-W-ICdimethylamino) sulfonyljurea

4-lsocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and A/,A/-dimethylsulfamide were used in general method C2 to give the titled compound as a white solid (29 mg, 31%). ¹H NMR (400 MHz, DMSO-de): δ = 7.96 (s, 1H), 6.94 (s, 1H), 2.81 (t, J = 8 Hz, 4H), 2.79 (s, 6H), 2.70 (t, J = 8 Hz, 4H), 2.02-1.96 (m, 4H). ¹³C NMR (150 MHz, DMSO-d₆): δ =

143.4, 142.9, 137.4, 125.1 117.9, 38.6, 32.9, 30.7, 25.5; LCMS (m/z): 324 [M +H]⁺; HRMS calculated for C15H21N3O3S1 (M+H)⁺ 324.13764, found 324.13891.

Example 4: /V-((9H-carbazol-9-yl)carbamoyl)-1-isopropyl-1 H-pyrazole-3sulfonamide

9H-carbazol-9-amine (1.0 g, 5.5 mmol) in THF (20 mL) was cooled to 0 °C and sodium hydride (0.45 g, 11 mmol) was added portion-wise. The reaction mixture was stirred for 30 mins then phenylchloroformate (1.72 g, 11 mmol) added drop-wise. The solution was allowed to warm to ambient temperature and stirred for a further 5h. The reaction was quenched using NaHCO₃ (aq) and the solution extracted using ethyl acetate. The organic phase was washed using water, brine then dried (Na₂SO₄) and concentrated in vacuo. The crude phenyl (9H-carbazol-9-yl)carbamate was purified by column chromatography on silica

WO 2017/140778

PCT/EP2017/053498

107 using 10% EtOAc:hexanes eluent and the resulting white solid used directly in the next synthetic step.

-lsopropyl-1 H-pyrazole-3-sulfonamide (0.1 g, 0.53 mmol) in THF (10 mL) was treated with NaH (60 mg, 1.06 mmol) and the reaction heated to 80 °C for 2h. The mixture was cooled to ambient temperature, phenyl (9H-carbazol-9yl)carbamate (2 equivalents) added and the reaction heated once more to 80 °C for 2h. On completion the reaction was diluted using sat. aq. NH₄CI and extracted using ethyl acetate (2 x 25 mL). The combined organics were washed with water, brine, dried (Na₂SO₄) and concentrated in vacuo. The product was purified using preparative thin layer chromatography on silica with 50% EtOAc:hexane to give the titled product as a white solid (15 mg, 7%).¹H NMR (400 MHz, CDsOD) δ 8.02 (d, J= 7.7 Hz, 2H), 7.72 (s, 1H), 7.41 -7.27 (m, 4H), 7.19 (t, J = 7.4 Hz, 2H), 6.70 (s, 1H), 4.59 (m, 1H), 1.48 (d, J = 6.6 Hz, 6H).

Copper Complexation of MCC950

Complex formation between the sodium form of MCC950 and copper chloride was tested and detected by using isothermal titration calorimetry (ITC). MCC950 (also known as CRID3) is a sulphonylurea having the formula:

An autolTC 200 (GE life sciences) was used to measure the change in heat induced by Cu²⁺-MCC950 interactions and data analysed using the MicroCai Origin version 7.0 software package adapted for auto-ITC data analysis.

Copper chloride (5 or 2.5mM of CuCI2) dissolved in water (miliQ water; Elga) was titrated into a cell containing 0.4 mM MCC950Na also dissolved in water.

The titration consisted of 19 x 2 pL injections at 25°C. As a control EDTA was used, in free acid form or as a sodium di-salt, at a concentration of 0.4 mM.

WO 2017/140778

PCT/EP2017/053498

108

Experiments were replicated three times and results were averaged. Thermograms and binding isotherms were used to determine the enthalpy (ΔΗ), binding constants (K), stoichiometry (N), and entropy (TAS) using a single-site binding model. The change in standard Gibbs free energy (AG) was calculated using the Gibbs-Helmholz thermodynamic equation: AG = -RTInK, where R is the ideal gas constant (1.985 cal mol'¹K'¹) and T is the temperature (298 K).

Copper (II) ions were seen to form astrong complex with MCC950, comparable to the complex with EDTAx2Na and much stronger than with EDTA free acid. Formation of MCC950:Cu(ll) complex was endothermic with enthalpy being positive thereby suggesting that the process was entropy driven with the presence of strong hydrophobic interactions. The thermodynamics are displayed in the table below and results are also shown in FIG 1:

Complex	N K	ΔΗ	TAS	AG
	(10⁴ M'¹)	(kcal mol'¹)	(kcal mol'¹)	(kcal mol'¹)
MCC950xNa:CuCI2	0.31 ±0.00 5.69 ±0.3	6.56 ±0.15	13.04 ±0.12	-6.48 ± 0.03

Biological Testing Methodology

NLRP3 inhibition assays

The following assays can be used to determine inhibitory activity of test compounds on the NLRP3 inflammasome using common stimuli such as adenosine triphosphate, nigericin, LeuLeu-OMe or monosodium urate crystals (MSU).

Cell culture

To generate HMDM (Human Monocyte Derived Macrophages), human monocytes are isolated from buffy coat blood using Ficoii-Piaque Plus (GE

WO 2017/140778

PCT/EP2017/053498

109

Healthcare) and density centrifugation. CD14⁺ cell selection is performed using MACS magnetic beads (Miltenyl Biotec). Isolated CD14⁺ monocytes are differentiated in culture for 7 days with 10 ng/ml human CSF-1 (Miltenyl Biotec) in Iscove’s modified Dulbecco’s medium (IMDM) containing L-glutamine supplemented with 10% FBS and 1 % penicillin/streptomycin (Life Technologies) as described by Croker et al2013 Immunol Cell Biol 91:625. Stably transfected ASC-cerulean macrophages as described by Hett et al. (Nat. Chem. Biol., 9, 398-405, 2013) are cultured in DMEM supplemented with 10% FCS and 1% P/S.

NLRP3 inflammasome activation assays

HMDM are seeded at 1 x 10⁵/ml. The following day the overnight medium is replaced and cells are stimulated with Escherichia coli serotype 0111 :B4 (Sigma Aldrich) for 3 h. Medium is removed and replaced with serum free medium (SFM) containing test compound 30 min prior to NLRP3 stimulation. Cells are then stimulated with: adenosine 5’-triphosphate disodium salt hydrate (5 mM 1 h), nigericin (10 μΜ 1 h), LeuLeu-OMe (1 mM 2 h) or MSU (200 pg/ml 15 h). ATP can be sourced from Sigma Aldrich, nigericin and MSU from Invivogen and LeuLeu-Ome from Chem-lmpex International.

Measurement of IL-1 β, IL-18, TNFa and cell death

For ELISA and cell death assays cells are seeded in 96 well plates. Supernatants are removed and analysed using ELISA kits according to the manufacturer’s instructions (DuoSet® R&D Systems, ReadySetGol® eBioscience, BD OptEIA™, or Perkin Elmer AlphaLISA®). Cell death is assessed by measurement of LDH release relative to a 100% cell lysis control using the CytoTox96® non-radioactive cytotoxicity assay (Promega).

Murine studies on compound levels in blood plasma and brain

General experimental: Carbutamide was purchased from Sigma Aldrich

WO 2017/140778

PCT/EP2017/053498

110 (Catalogue No. 381578). Acetonitrile was Chromasolv® HPLC grade (Sigma Aldrich, Sydney, Australia), the formic acid was AR grade 99%-100% Normapur (VWR International Pty Ltd, Brisbane, Australia), DMSO was ReagentPlus® grade (D5879, Sigma Aldrich, Sydney, Australia) and the H₂O Milli-Q was filtered. The HPLC vial and polypropylene inserts from Agilent Technologies (Melbourne, Australia), while the 1.5 mL Eppendorf tubes Protein LoBind Tubes were from VWR International Pty Ltd (Brisbane, Australia).

Preparation of precipitation solution: 100 mL ACN and 5 pL of 10 mM carbutamide in DMSO (ACN with 135 ng/mL carbutamide MS internal standard).

Preparation of standard curve in plasma: A 1 mg/mL of test compound in 10 mM NH4HCO3 was prepared and diluted 10-fold to give a 100,000 ng/mL stock solution. A series of 10-fold dilutions of the 100,000 ng/mL stock solution with 10 mM NH4HCO3 gave concentrations of 10,000, 1,000, 100 and 10 ng/mL. The 100,000 ng/mL stock solution was diluted to 3: 7 with 10 mM NH4HCO3 to give a concentration of 30,000 ng/mL and a series of 10-fold dilutions gave concentrations of 3,000, 300, 30 and 3 ng/mL.

pL of test compound-containing solution and 160 pL precipitation solution were added to 20 pL of mouse plasma in a low binding Eppendorf tube. The samples were vortexed, allowed to stand at 4 °C for 10 mins and centrifuged at 14,000 x c?for 8 min. 150 pL of the supernatant was transferred to an HPLC vial insert. The samples were stored at 4 °C until analysis.

Preparation of standard curve in brain homogenate: The sample solutions prepared for the plasma standard curve were used for the brain homogenate standard curve.

The mouse brain homogenate from the saline control was thawed and vortexed for 3 min or until homogenous, sonicated for 1 min. When the foam settled, 50 pL of mouse brain homogenate was transferred into an Eppendorf tube, followed by 50 pL of test compound in 10 mM NH4HCO3, 150 pL of H₂O and

WO 2017/140778

PCT/EP2017/053498

111

500 μΙ_ of ice cold precipitation solution with vortexing after every addition. The standards were allowed to stand at 4 °C for 10 mins and then centrifuged at

14,000 x g for 8 min. 200 μΙ_ of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles were present and the samples stored at 4 °C until analysis.

Dosing of mice and transcardial perfusion

Dosing: Oral gavage at 20 mg/kg

Time point: 2 hour

Prepare stock compounds for dosing at 4 mg/ml in sterile PBS. Mice were weighed and dosed by oral gavage at 20 mg/kg for each compound. After 2 hours mice were anesthetized using a combination of Zoletil (50 mg/kg) and Xylazine (10 mg/kg) and blood was collected by cardiac puncture into tubes containing 20 μΙ_ of 100 mM EDTA. The blood was centrifuged at 2000 x g for 15 minutes at 4 °C to collect plasma.

Preparation of plasma samples for analysis: 20 μΙ_ of NH4HCO3 and 160 plprecipitation solution were added to 20 pL of mouse plasma in a low binding Eppendorf tube. The samples were vortexed, allowed to stand at 4 °C for 10 mins and centrifuged at 14,000 χ g for 8 min. 150 pL of the supernatant was transferred to an HPLC vial insert ensuring that no air bubbles were present. The samples were stored at 4 °C until analysis.

Brain homogenate preparation: The brains of mice were perfused with PBS for 5 minutes then dissected and weighed. Brain homogenate was prepared by homogenizing total brain (0.5 g) with 4 volumes (2 ml) of deionized water and stored at -20 °C before analysis. The homogenate was thawed, vortexed for 3 min or until homogenous, and sonicated for 1 min. When the foam settled, 50 pL of mouse brain homogenate was transferred into an Eppendorf tube, followed by 50 pL of 10 mM NH4HCO3, 150 pL of H₂O and 500 pL of ice cold precipitation solution with vortexing after every addition. 200 pL of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles

WO 2017/140778

PCT/EP2017/053498

112 were present and the samples stored at 4 °C until analysis.

Preparation of brain samples for analysis: 50 μΙ_ of mouse brain was transferred into an Eppendorf tube, followed by 50 μΙ_ of 10 mM NH₄HCO₃,150 μΙ_ of H₂O and 500 μΙ_ of ice cold precipitation solution with vortexing after every addition. The solutions were allowed to stand at 4 °C for 10 mins and then centrifuged at 14,000 χ g for 8 min. 200 μΙ_ of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles were present and the samples stored at 4 °C until analysis.

LC-MS/MS: The samples were analysed on an AB Sciex 4000QTrap MS with 2 Shimadzu Nexera LC-30AD Solvent Delivery Units, Shimadzu Nexera SIL30AC Auto-Sampler, Shimadzu Prominence DGU-20A₅ Degasser, Shimadzu Prominence CBM-20A System Controller and Shimadzu Prominence CTO-20A Column Oven. The column oven was set to 40 °C, while the Autosampler was set to 15 °C. 2 μΙ_ injections were made and MS analyses were undertaken in Selected Reaction Monitoring (SRM) mode using Turbo Spray (-)-ESI with Low Resolution Q1 and Low Resolution Q3. MS parameters: CUR: 30.00, IS: 4300.00, TEM: 500.00, GS1: 50.00, GS2: 50.00, ihe: ON, CAD: High, DP 60.00, EP -10.00, CXP -15.00. MCC950 SRM: Q1 403.2 to Q3 204.3 Da, dwell 150 msec, CE -27 and carbutamide (IS) SRM: Q1 270.0 to Q3 171.0 Da, dwell 100 msec, CE -25. HPLC Column: Waters Atlantis® T3 5 pm 2.1 χ 50mm with Atlantis® T3 5 pm 2.1 χ 10 mm guard column. Flow rates and solvent: 0.35 ml/min, solvent A: 0.1% formic acid in H₂O, solvent B: 0.1% formic acid in ACN; isocratic 2% B from 0->2 mins, gradient 2%->100% B from 2->5 mins, isocratic 100% from 5->9 mins, gradient 100%->2% B from 9->9.1 mins and isocratic 2% B from 9.1->13 mins. The peak areas from the SRM data for carbutamide and test compound were analysed using the AB Sciex’s Analyst software using the Quantitation Wizard. The peak area was plotted against the ng/mL concentration in 20 pL 3 to 30,000 ng/mL test compound solutions and the lower and upper range of linear response was determined. These data were then plotted in Microsoft Excel and the linear response equation used to

WO 2017/140778

PCT/EP2017/053498

113 determine the test compound concentration in the 20 μΙ_ plasma solutions.

Similarly, for the brain homogenate samples, the peak areas of the 50 μΙ_ 3 to

3,000 ng/ml_ test compound solutions were used to determine the test compound concentration in the 50 μΙ_ brain homogenate solutions.

RESULTS

Ex	Compound structure	Compound name	tPS A	M.W
1	<XX> Y/q.	N-((1,2,3,5,6,7-hexahydro-s- indacen-4-yl)carbamoyl) morpholine-4-sulfonamide	88	365
2		N-((1,2,3,5,6,7-hexahydro-sindacen-4-yl)carbamoyl)-4methylpiperazine-1sulfonamide	90	378
3		N-[1,2,3,5,6,7-hexahydro-s- indacen-4-yl]-N'- [(dimethylamino)sulfonyl]urea	79	323
4	Ώ O_v -----/ I vv \ ^H 0	N-((9H-carbazol-9- yl)carbamoyl)-1 -isopropyl-1H- pyrazole-3-sulfonamide	106	397

Table 1: Topological Polar Surface Area (tPSA) and molecular weight of select compounds.

WO 2017/140778

PCT/EP2017/053498

114

Ex	Name	Chem Formula	HRMS formula	HRMS Calc	HRMS found	Avg. IL-1 β IC50 HMDM (nM)
2	N-((1,2,3,5,6,7hexahydro-sindacen-4yl)carbamoyl)-4methylpiperazin e-1-sulfonamide	C18H26N4O3S	C18H27N4O3S1	379.1798	379.1795	+++
4	N-((9H-carbazol9-yl)carbamoyl)1 -isopropyl-1 Hpyrazole-3sulfonamide	C19H19N5O3S	C19H20N5O3S	398.1281	398.1282	++

Table 2: Inhibition of IL-1 β release IC50 in nM cell based assay using HMDM (<1 μΜ = ‘+++’ / <10 μΜ = ‘++’ / <50 μΜ = ‘+’). (ESI+ for all compounds)

Examples 5-43

Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHZ; the chemical shifts are reported in parts per million. Spectra were recorded using a Bruker Avance III spectrometer at 400 MHz fitted with a BBO5mm liquid probe. Mass spectra were recorded with a Waters Acquity UPLC system equipped with Acquity UPLC BEH. Mobile phases typically consisted of acetonitrile mixed with water containing 10mM ammonium bicarbonate.

Preparative HPLC was carried out using a Waters Xbridge BEH C18, 5 pm, 19x50 mm column using a gradient MeCN in aqueous 10 mM ammonium bicarbonate. Fractions were collected following detection by mass with positive and negative ion electrospray detector on a Waters FractionLynx LCMS.

WO 2017/140778

PCT/EP2017/053498

115 ((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl chloride

A stirred solution of chlorosulfonyl isocyanate (2.63 ml, 30.3 mmol) in diethyl ether (20 mL) was cooled to -20 °C, then a solution of 1,2,3,5,6,7-hexahydro-sindacen-4-amine (5 g, 28.9 mmol) in diethyl ether (100 mL) was added slowly over 10 minutes. The reaction was stirred for 1 hour, then most of the ether removed in vacuo. Iso-hexane (200 mL) was added and the mixture was sonicated for 5 minutes. The solid was filtered and dried overnight to afford the title compound (7.5 g).

1H NMR (400 MHz, CDCI₃) δ 7.95 (s, 1H), 7.10 (s, 1H), 2.93 (t, J = 7.5 Hz, 4H), 2.86 (t, J = 7.4 Hz, 4H), 2.11 (p, J = 7.4 Hz, 4H) (exchangeable proton not visible).

General procedure

Amines (0.1 mmol) were pre-dissolved in DMA (0.5 mL), then 4methylmorpholine (0.040 g, 0.400 mmol) was added. A solution of ((1,2,3,5,6,7hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl chloride (0.025 g, 0.08 mmol) in THF (1 mL) was added to each well, the reactions were capped and shaken overnight at room temperature. The samples were purified by RPHPLC; Waters X-Bridge BEH C18 prep column, 5 pm, 10x50mm, Basic (0.1% ammonium bicarbonate) 6.5 min method, 10-40% acetonitrile. Examples 5-40 shown in Table 3 below were prepared this way.

WO 2017/140778

PCT/EP2017/053498

116

Ex	Structure	Exact mass	LCMS Mass ion	Retention time
5	7¾%¾	449.1	450.1	1.3
	1-{[2-(2-chlorophenoxy)ethyl]sulfamoyl}-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea
6		437.1	438.1	1.3
	1-{[(4-chloro-2-fluorophenyl)methyl]sulfamoyl}-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea
7	xx x vXV	463.1	464.1	1.03
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[(3- methanesulfonylphenyl)methyl]sulfamoyl}urea
8	......i' %	424.2	425.2	1.24
	1 -(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[(1 Hindol-2-ylmethyl)sulfamoyl]urea

WO 2017/140778

PCT/EP2017/053498

117

9	1-{[(4-chloro-2-methylphenyl)met (1,2,3,5,6,7-hexahydro-s-indacer	V hyl]sulfamoyl}-3i-4-yl)urea	433.1	434.1	1.36
10			rtCF₃ /
		Q		A Ύ		469.1	470.1	1.35
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -({[2- (trifluoromethoxy)phenyl]methyl}sulfamoyl)urea
11		“Π			)	439.1	440.1	1.21
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[(2,4,6-
	trifluorophenyl)methyl]sulfamoyl}urea
12		Q	\ o' Η H \			448.3	449.3	1.09

	[ethyl(methyl)amino]cyclohexyl}methyl)sulfamoyl]- 3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea

WO 2017/140778

PCT/EP2017/053498

118

13	<xx> I H ,0 ΎΥη —O 3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -({4-[2-	474.2	475.2	1.29
(thiophen-2-)	/l)ethyl]piperazin-1-yl}sulfonyl)urea
14			Λ	~\
	r\
			'W JL J // yY	Ί Ύ	)	375.1	376.1	1.09
	1 -[(furan-2-ylmethyl)sulfamoyl]-3-(1,2,3,	5,6,7-
	hexahydro-s-indacen-4-yl)urea
15			lj n 0	X
	<J		1	Y		406.1	407.1	1.01
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[2-(1,3-
	thiazol-2-yl)ethyl]sulfamoyl}urea
16

		^H /9 HN N / Y /-Q			406.2	407.2	1.05
	3-(1,2,3,5,6,7-hexahydro-s-indac	en-4-yl)-1-{[4-

WO 2017/140778

PCT/EP2017/053498

119

	(propan-2-yl)piperazin-1-yl]sulfonyl}urea
17	A ( 1 -[(furan-2-ylmethyl)[2-(morpho yl)ethyl]sulfamoyl]-3-(1,2,3,5,6,/ indacen-4-yl)urea	A X in-4'-hexa!	‘l lydro-s-	488.2	489.2	1.24
18	A .. < \ /Αχ/ 1 1 /W 3-{[2-(dimethylamino)ethyl](thio ylmethyl)sulfamoyl}-1 -(1,2,3,5,6 indacen-4-yl)urea	A 'x Dhen-3 ,7-hexi	ahydro-s-	462.2	463.2	1.27
19	-^Ajxx) 1 -[benzyl(1,3-thiazol-2-ylmethyl (1,2,3,5,6,7-hexahydro-s-indace	A A Isulfarr ;n-4-yl)	) oyl]-3- urea	482.1	483.2	1.29
20	1 -(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-	482.1	483.2	1.47

WO 2017/140778

PCT/EP2017/053498

120

	{methyl[(2-phenyl-1,3-thiazol-4yl)methyl]sulfamoyl}urea
21	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 - ({2-[3(pyridin-3-yl)-1,2,4-oxadiazol-5yl]ethyl}sulfamoyl)urea	468.2	469.2	0.96
22	3-({[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5yl]methyl}sulfamoyl)-1 -(1,2,3,5,6,7-hexahydro-sindacen-4-yl)urea	513.2	514.2	1.13
23	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 - [(thiophen-2-ylmethyl)sulfamoyl]urea	391.1	392.1	1.09
24	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[2-(4- methylphenoxy)ethyl]sulfamoyl}urea	429.2	430.2	1.5

WO 2017/140778

PCT/EP2017/053498

121

25	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -[(3phenylpropyl)sulfamoyl]urea	413.2	414.2	1.38
26	Π	r	η ο o yv
			UM	429.2	430.2	1.5
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[2-(2- methylphenoxy)ethyl]sulfamoyl}urea
27			n 0
		rY/A/A
	a		451.2	452.2	1.09
	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -{[4-(2methyl-1 H-imidazol-1 -yl)phenyl]sulfamoyl}urea
28

		YVp	397.1	398.2	1.21
	1 -(2,3-dihydro-1 H-indole-1 -su Ifo nyl)-3-( 1,2,3,5,6,7hexahydro-s-indacen-4-yl)urea

WO 2017/140778

PCT/EP2017/053498

122

29	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 - [methyl(pyridin-4-ylmethyl)sulfamoyl]urea	400.2	401.2	0.91
30	Ή = ζΧ 1 i / 3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 - [(pyridin-4-ylmethyl)sulfamoyl]urea	386.1	387.1	0.93
31	O' A ## 3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 - [methyl(phenyl)sulfamoyl]urea	385.1	386.2	1.21
32	1-{[(4-fluorophenyl)methyl](methyl)sulfamoyl}-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea	417.2	418.2	1.22
33	1-[(3-cyano-4-methylphenyl)sulfamoyl]-3-	410.1	411.1	1.13

WO 2017/140778

PCT/EP2017/053498

123

	(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea
34	3-[(1,3-diethyl-6-methyl-2-oxo-2,3-dihydro-1 H-1,3benzodiazol-5-yl)sulfamoyl]-1 -(1,2,3,5,6,7hexahydro-s-indacen-4-yl)urea	497.2	498.2	1.1
35	3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-1 -[(6- methoxy-4-methylpyridin-3-yl)sulfamoyl]urea	416.2	417.2	1.1
36	x/ax 1 -[(6-acetyl-2H-1,3-benzodioxol-5-yl)sulfamoyl]-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ure	457.1	458.1	1.11
37	Λ 5kX XX 1 -[(2,3-dihydro-1 H-inden-4-yl)sulfamoyl]-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea	411.2	412.2	1.27

WO 2017/140778

PCT/EP2017/053498

124

38	1-[(4,7-dimethyl-2-oxo-2H-chromen-6-yl)sulfamoyl]- 3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea	467.2	468.2	1.09
39	ly/1 QaAAJ 1-[(2,4-dimethylpyridin-3-yl)sulfamoyl]-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea	400.2	401.2	1.02
40	1 -{[2-(2,3-dihydro-1 H-indol-1 -yl)ethyl]sulfamoyl}-3- (1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea	440.2	441.2	1.38

Table 3

Example 41: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4methyl-piperazine-1 -sulfonamide

1-Methylpiperazine (70 μΙ, 0.631 mmol) was added to a suspension of ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl chloride (50 mg,

0.159 mmol) in THF (1 mL). The reaction mixture was stirred at room

WO 2017/140778

PCT/EP2017/053498

125 temperature overnight. DMF (1 mL) was added to aid solubility, the mixture was stirred for a further 1 hour, then filtered through a plug of cotton wool and purified by preparative HPLC to afford the title compound (2.8 mg) as a colourless solid.

¹H NMR (400 MHz, D₂O/NaOD) δ 6.82 (s, 1H), 2.89 (br s, 4H), 2.59 (t, J = 7.5 Hz, 4H), 2.48 (t, J = 7.3 Hz, 4H), 2.26 (br s, 4H), 1.97 (s, 3H), 1.76 (p, J = 7.5 Hz, 4H).

LCMS m/z 379 (M+H)⁺ (ES⁺); 377 (M-H)’ (ES’)

Example 42: 1 -(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[(1 -methyl-1 Hindazol-6-yl)sulfamoyl]urea

CIO· ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl chloride (75 mg, 0.238 mmol) was added to a solution of 1 -methyl-1 H-indazol-6-amine (105 mg, 0.715 mmol) in THF (2 mL). The mixture was stirred for 6 hours, filtered, then purified by preparative HPLC to afford the title compound (2.3 mg).

¹H NMR (400 MHz, D₂O/NaOD) δ 7.53 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 6.77 (s, 1H), 6.60 (s, 1H), 6.46 (dd, J = 8.7,1.8 Hz, 1H), 2.37 (t, J = 7.5 Hz, 4H), 2.36 (s, 3H), 1.97 (t, J = 7.5 Hz, 4H), 1.41 (p, J = 7.5 Hz, 4H).

LCMS m/z 426 (M+H)⁺ (ES⁺); 424 (M-H)’ (ES’)

WO 2017/140778

PCT/EP2017/053498

126

Example 43: 3-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-1 -[(1 H-indol-5yl)sulfamoyl]urea

CIO

H-lndol-5-amine (84 mg, 0.635 mmol) and triethylamine (150 μΙ, 1.076 mmol) were dissolved in THF (2 mL). ((1,2,3,5,6,7-Hexahydro-s-indacen-4yl)carbamoyl) sulfamoyl chloride (100 mg, 0.318 mmol) was then added as a solid, the mixture was stirred for 30 minutes, filtered and purified by preparative HPLC to afford the title compound (7 mg) as a pale brown solid.

¹H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.85 (s, 1H), 9.70 (s, 1H), 7.64 (s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.37 (t, J = 2.8 Hz, 1H), 7.34 (d, J = 8.6 Hz, 1H), 7.00 (dd, J = 8.6, 2.0 Hz, 1H), 6.94 (s, 1H), 6.39 - 6.36 (m, 1H), 2.81 (t, J = 7.4 Hz, 4H), 2.58 (t, J = 7.4 Hz, 4H), 1.95 (p, J = 7.5 Hz, 4H).

LCMS m/z 411 (M+H)⁺ (ES⁺); 409 (M-H)’ (ES’)

Biological Assay

NLRP3 and Pyroptosis

It is well established that the activation of NLRP3 leads to cell pyroptosis and this feature plays an important part in the manifestation of the clinical disease (Yan-gang Liu et al., Cell Death & Disease, 2017,8(2), e2579; Alexander Wree et al., Hepatology, 2014, 59(3), 898-910; Alex Baldwin et al., Journal of Medicinal Chemistry, 2016, 59(5), 1691-1710; Ema Ozaki et al., Journal of Inflammation Research, 2015, 8, 15-27; Zhen Xie & Gang Zhao, Neuroimmunology Neuroinflammation, 2014, 1 (2), 60-65; Mattia Cocco et al., Journal of Medicinal Chemistry, 2014, 57(24), 10366-10382; T. Satoh et al.,

WO 2017/140778

PCT/EP2017/053498

127

Cell Death & Disease, 2013,4, e644). Therefore, it is anticipated that inhibitors of NLRP3 will block pyroptosis, as well as the release of pro-inflammatory cytokines (e.g. IL-1 β) from the cell.

THP-1 Cells: Culture and Preparation

THP-1 cells (ATCC # TIB-202) were grown in RPMI containing L-glutamine (Gibco #11835) supplemented with 1 mM sodium pyruvate (Sigma # S8636) and penicillin (100units/ml)/streptomycin (0.1 mg/ml) (Sigma# P4333) in 10% Fetal Bovine Serum (FBS) (Sigma # F0804). The cells were routinely passaged and grown to confluency (~10⁶cells/ml). On the day of the experiment, THP-1 cells were harvested and resuspended into RPMI medium (without FBS). The cells were then counted and viability (>90%) checked by Trypan blue (Sigma # T8154). Appropriate dilutions were made to give a concentration of 625,000cells/ml. To this diluted cell solution was added LPS (Sigma# L4524) to give a 1pg/ml Final Assay Concentration (FAC). 40μΙ of the final preparation was aliquoted into each well of a 96-well plate. The plate thus prepared was used for compound screening.

THP-1 Cells Pyroptosis Assay

The following method step-by-step assay was followed for compound screening.

1. Seed THP-1 cells (25,000cells/well) containing 1.Opg/rnl LPS in 40μΙ of RPMI medium (without FBS) in 96-well, black walled, clear bottom cell culture plates coated with poly-D-lysine (VWR # 734-0317)

2. Add 5μΙ compound (8 points half-log dilution, with 10μΜ top dose) or vehicle (DMSO 0.1% FAC) to the appropriate wells

3. Incubate for 3hrs at 37°C in 5% CO₂

4. Add 5μΙ nigericin (Sigma # N7143) (FAC 5μΜ) to all wells

WO 2017/140778

PCT/EP2017/053498

128

5. Incubate for 1 hr at 37^QC and 5% CO₂

6. At the end of the incubation period, spin plates at 300xg for 3mins and remove supernatant

7. Then add 50μΙ of resazurin (Sigma # R7017) (FAC 100 μΜ resazurin in RPMI medium without FBS) and incubate plates for a further 1 -1,5h at 37^QC and 5% CO₂

8. Plates were read in an Envision reader at Ex 560nm and Em 590nm

9. IC₅o data is fitted to a non-linear regression equation (log inhibitor vs response-variable slope 4-parameters)

96-we 11 Plate Map

A	1	n r Z. ϊ Comp 1	3 Como 2	4 Comp 3	5 Comp 4
B		Como 1	Como 2	Comp 3	Como 4
i C		Comp 1	Como 2	Comp 3	Como 4
D		Como 1	Coma 2	Como 3	Como 4
E		Como 1	Como 2	Como 3	Comp 4
; F		Comp 1	Como 2	Como 3	Como 4
G		Comp 1	Coma 2	Como 3	Como 4
H		Como 1	Como 2	Como 3	Como 4

6	7 :	g	9	10	11
Como 5	Como 6	Como 7	Como S	Comp 9	Comp 10
Como 5	Como 6	Comp 7	Como S	Como 9	Como 10
Como 5	Como 6	Como 7	Como S	Como 9	Como 10
Co no 5	Comp 6	Co mo 7	Como 3	Comp 9	Como 10
Como 5	Coma 6	Como 7	Como 3	Como 9	Como 10
Comp 5	Comp 6	Comp 7	Como 8	Co tip 9	Como 10
Como 5	Comp 6	Como 7	Como 8	Coma 9	Como 10
Comp 5	Comp 6	Comp 7	Como 8	Como 9	Como 10

Comooeno 3-oo t faif-Og G''Lit o^r

B1CC950 (lOi MJ '>/* D'Lgf^ree cotOi

The results of the pyroptosis assay performed are summarised in Table 4 below.

Example No.	IC50 (nM)	Example No.	IC50 (nM)
5	++	6	++
7	++	8	not measured
9	not measured	10	not measured
11	++	12	++
13	++	14	++
15	++	16	not measured
17	+	18	++

129

WO 2017/140778

PCT/EP2017/053498

19	+++	20	++
21	++	22	not measured
23	++	24	++
25	++	26	++
27	++	28	++
29	++	30	+
31	++	32	++
33	++	34	++
35	+++	36	++
37	++	38	not measured
39	++	40	++
41	not measured	42	+++
43	+++

Table 4: Results of pyroptosis assay (<1 μΜ = “+++’ / <10 μΜ = “++’ / <50 μΜ = +’)

WO 2017/140778

PCT/EP2017/053498

130

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

Formula (I) wherein Q is selected from O, S and Se;

J is S or Se;

W¹ and W², when present, are independently selected from N and C;

R¹ and R² are independently selected from the group consisting of hydrogen, Ci-Ci₂ alkyl, C2-C12 alkenyl, C₂-Ci₂ alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W¹ and W² is present and is a nitrogen atom and when R¹ or R² are cyclic then the respective W¹ or W² may form part of the ring structure.

2. The compound of claim 1, wherein R¹W¹- is (R¹)2N- or (R¹)HN- or (R¹)-, and wherein -W²R² is -N(R²)2 or -NH(R²) or -(R²), provided that a nitrogen atom of R¹W¹- and/or a nitrogen atom of -W²R² is linked to the remainder of the molecule.

3. The compound of claim 1 or claim 2, wherein -W²R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl group is fused to one or

WO 2017/140778

PCT/EP2017/053498

131 more cyclic hydrocarbon, heterocyclic, aryl or heteroaryl rings, wherein -W²R² may be optionally substituted.

4. The compound of any one of the preceding claims, wherein:

R¹W¹- comprises a heteroaryl group, wherein R¹W¹- may be optionally substituted;

a nitrogen atom of R¹W¹- is linked to J; and

-W²R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the a and a' positions, wherein -W²R² may optionally be further substituted.

5. The compound of any one of the preceding claims, wherein R¹W¹- is R¹NH- or (R¹)₂N- wherein at least one R¹ comprises a fused bicyclic group, or two R¹ together with the nitrogen atom to which they are attached form a fused bicyclic group, wherein R¹W¹- may be optionally substituted.

6. The compound of any one of the preceding claims, wherein at least one of W¹ and R¹ or W² and R² combine to form a moiety selected from the group consisting of:

WO 2017/140778

PCT/EP2017/053498

132

ΛΑ — N N—R³ «ΛΛΛΡ

R³

ΛΠΛΓ o

R³ wherein, each dashed line may independently be a bond;

T is O or S;

each incidence of R³ is independently selected from the group consisting of hydrogen, halide, cyano, Ci-C₆ alkyl, Ci-C₆ trifluoroalkyl, Ci-C₆ alkoxy, C=O,

WO 2017/140778

PCT/EP2017/053498

133

SO₂, acyl, amino, hydroxyl, C₅-C₆ heteroaryl, C₅-C₆ heterocyclyl and C₃-C₆ cycloalkyl, each of which may be optionally substituted as appropriate; and n is 0, 1,2 or 3.

7. The compound of any one of the preceding claims, wherein the compound of formula (I) is selected from a compound of formula (II), (III), (IV), (V) or (VI) or a pharmaceutically acceptable salt, solvate or prodrug thereof:

Formula II

Formula III

Formula IV

R¹⁵

Formula VI

WO 2017/140778

PCT/EP2017/053498

134 wherein W¹ and W², if present, and R¹ and R² are as described in any one of the preceding claims;

each incidence of R¹⁵ is independently selected from Ci to C₄ alkyl, Ci to

C₄ hydroxylalkyl and C₃ to C₅ cycloalkyl; and

A is optionally substituted heteroaryl or heterocycle, linked to the sulfonyl sulphur through a ring nitrogen.

8. The compound of claim 7, wherein:

(i) R¹ or A is selected from pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, such as indole, each of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with Ci-C₆ alkyl; or (ii) R¹ or A is independently selected from pyrazole or triazole, optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with Ci-C₆ alkyl.

9. The compound of claim 7 or claim 8, wherein R¹⁵ is selected from isopropyl, cyclopropyl and C₃ to C₅ hydroxylalkyl.

10. The compound of any one of the preceding claims wherein the compound, or pharmaceutically acceptable salt, solvate or prodrug thereof, is an inhibitor of the NLRP3 inflammasome.

WO 2017/140778

PCT/EP2017/053498

135

11. A pharmaceutical composition comprising a compound of any one of claim 1 to claim 10, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

12. A method of treatment or prevention of a disease, disorder or condition including the step of administering an effective amount of a compound of any one of claim 1 to claim 10, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the pharmaceutical composition of claim 11, to thereby treat or prevent the disease, disorder or condition.

13. The method of claim 12, wherein the disease, disorder or condition is one which is responsive to:

(i) inhibition of activation of the NLRP3 inflammasome; and/or (ii) modulation of one or more of IL-1 β, IL-17, IL-18, IL-1 oc, IL-37, IL-33 and Th17 cells.

14. The method of claim 12 or claim 13, wherein the disease, disorder or condition is:

(i) a disease, disorder or condition of the immune system;

(ii) an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition;

(iii) a disease, disorder or condition of the skin;

(iv) a disease, disorder or condition of the cardiovascular system;

(v) a cancer, tumour or other malignancy;

(vi) a disease, disorder or condition of the renal system;

(vii) a disease, disorder or condition of the gastro-intestinal tract;

WO 2017/140778

PCT/EP2017/053498

136 (viii) a disease, disorder or condition of the respiratory system;

(ix) a disease, disorder or condition is of the endocrine system; and/or (x) a disease, disorder or condition is of the central nervous system (CNS).

15. The method of claim 12 or claim 13, wherein the disease, disorder or condition is selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID), autoinflammatory diseases, familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID) and sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren’s syndrome and Schnitzler syndrome; macrophage activation syndrome; Blau syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), asthma such as allergic asthma and steroidresistant asthma, asbestosis, silicosis and cystic fibrosis; dermatitis including contact dermatitis; central nervous system diseases including Parkinson’s disease, Alzheimer’s disease, motor neuron disease, Huntington’s disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudogout; ocular diseases including those of the ocular epithelium, age-related

WO 2017/140778

PCT/EP2017/053498

137 macular degeneration (AMD), uveitis, corneal infection and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy, nephrocalcinosis and diabetic nephropathy; liver disease including nonalcoholic steatohepatitis (NASH) and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, relapsing polychondritis; viral infections including alpha virus (Chikungunya, Ross River) and flavivirus (Dengue, Zika), flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia; polymyositis; stroke including ischemic stroke; myocardial infarction including recurrent myocardial infarction; congestive heart failure; embolism; cardiovascular disease; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; ischaemia reperfusion injury and diseases where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

16. The method of claim 12 or claim 13, wherein the disease, disorder or condition is:

(i) an autoinflammatory disease such as cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), Neonatal onset multisystem inflammatory disease (NOMID), Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor antagonist (DIRA), Majeed syndrome, or pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA);

(ii) Parkinson’s disease or Huntington’s disease;

WO 2017/140778

PCT/EP2017/053498

138 (iii) gout or juvenile idiopathic arthritis;

(iv) non-alcoholic steatohepatitis (NASH);

(v) oxalate nephropathy or nephrocalcinosis;

(vi) uveitis;

(vii) hidradenitis suppurativa (HS); or (viii) myelodisplastic syndrome, macrophage activation syndrome, Schnitzler syndrome, adult-onset Still’s disease, or Behpet’s Disease.

17. The method of any one of claim 12 to claim 16 wherein the treatment or prevention of the disease, disorder or condition is performed on a mammal, such as a human subject.

18. A method of diagnosing a disease, disorder or condition in a mammal including the step of administering a labelled compound of any one of claim 1 to claim 10, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or metal ion chelate complex thereof, to the mammal or to a biological sample obtained from the mammal to facilitate diagnosis of the disease, disorder or condition in the mammal.

19. A method of modulating the activity of a biological target comprising the step of exposing the biological target to a compound of any one of claim 1 to claim 10, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

20. The method of claim 19 wherein the biological target may be selected from the group consisting of the NLRP3 inflammasome, IL-1 β, IL-17, IL-18, IL1 oc, IL-37, IL-33 and Th17 cells.

WO 2017/140778

1/1

PCT/EP2017/053498

CaCI2 SmMtoEDTA 04mM in MESIOmM kcal mol' of injectant ₍ pcal/sec kcal _mo) t _{Qf injectant}

CaCI25mMtoMCC950NaC4mM

CuCI2_5mMtoEDTA2Na_04mM

CuCI2 5mM to MCC950Na 0.4mM

FIG 1